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Abstract (In English) 
Abstract 
Osteoporosis, which is a skeletal disorder characterized by 
compromised bone strength predisposing a person to an increased risk of 
fracture, occurs most frequently in postmenopausal women. Its associated 
fractures are one of the major causes of illness, disability and death. This 
makes postmenopausal osteoporosis a major worldwide public health 
concerns. Current treatment regimes of this disease decrease the incidence 
of fractures. However, most of them are not suitable for the long-term care. 
Alternative treatment regimes are needed. 
Kidney-tonifying herbs are considered to be beneficial to bone health 
in traditional Chinese medicine. Our laboratory's animal study using eleven-
month-old ovariectomized adult Sprague-Dawley rats with low bone mineral 
densities (BMD) revealed that daily administrations of the aqueous and 
ethanol extracts of a Kidney-tonifying herbal formula, ELP, which was 
composed of Herba Epimedii (Epimedium), Fructus Ligustri Lucidi (Ligustrum) 
and Fructus Psoraleae {Psoralea), and its two major ingredients Epimedium 
and Ligustrum, reduced BMD loss significantly in 18 weeks. 
Based on this finding, investigations of the effects of these herbal 
extracts on bone metabolism and calcium homeostasis, both of which play 
important roles in the pathogenesis of postmenopausal osteoporosis, were 
conducted. The results demonstrated that the aqueous and ethanol extracts 
of the Kidney-tonifying herbs and herbal formula modulated the expressions 
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of the calcium absorption and reabsorption-related genes of ovariectomized 
adult rats. The ethanol extract of the ELP induced the gene expression of 
renal 25-hydroxyvitamin D3-I alpha-hydroxylase, which plays an important 
role in calcium homeostasis by catalyzing the synthesis of 1,25-
dihydroxyvitamin D3 (1，25(OH)2D3). The ethanol extract of Ligustrum 
increased the mRNA level of duodenal vitamin D receptor (VDR), which is 
the mediator of 1’25(OH)2D3-jnduced calcium absorption. The aqueous 
extracts of Epimedium and ELP upregulated the gene expressions of renal 
VDR and calbindin-D28K respectively, which are involved in calcium 
reabsorption. Apart from having significant effects on the expressions of 
genes related to calcium absorption and reabsorption, the aqueous extract of 
Ligustrum also modulated the bone mineralization of rat osteoblastic UMR-
106 cells and the aqueous extract of Epimedium showed estrogen receptor 
binding activity in human breast cancer MCF-7 cells. 
These observations reveal that the selected Kidney-tonifying herbal 
extracts positively modulate calcium homeostasis and bone matrix 
mineralization, which could favor bone protection, and estrogen receptor may 
be one of the mediators of these actions. This suggests the potential clinical 
use of the aqueous and ethanol extracts of the Kidney-tonifying herbal 
formula, ELP, and its major ingredients, Epimedium and Ligustrum on the 
treatment of postmenopausal osteoporosis. 
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Chapter 1. Introduction 
Chapter 1. Introduction 
1.1 Osteoporosis 
1.1.1 Consensus statement 
Osteoporosis is defined as "a skeletal disorder characterized by 
compromised bone strength predisposing a person to an increased risk of 
fracture. Bone strength primarily reflects the integration of bone density and 
bone quality". (NIH Consensus Development Panel on Osteoporosis 
Prevention, Diagnosis, and Therapy, 2000). This reveals the inverse 
relationship between low bone strength and increased fracture risks, which 
provides a basis to identify individuals at high risk of osteoporosis. Bone 
mineral density (BMD) testing is noninvasive and currently the most objective 
method to diagnose osteoporosis in asymptomatic women (National 
Osteoporosis Foundation, 1998). The diagnostic criteria of this disease are 
thus based on bone density measurements expressed in T-scores, in which 
osteoporosis is defined as a value for BMD 2.5 SD or more below the young 
adult reference mean (T-score is equal to or less than -2.5) (Table 1-1; 
Figure 1-1) (World Health Organization, 1994). 
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Table 1-1. Diagnostic Criteria for Osteoporosis with Densitometry 
Condition ^ .‘ . 
Cntenon 
, BMD greater than 1 SD below the young adult female 
No�mai mean (T-score^1) 
BMD greater than 1 SD below the young adult female 
Osteopenia mean, but less than 2.5 SD below this value (T score < 一 1 
and >-2-5) 
A BMD 2.5 SD or more below the young adult female mean 
Osteoporosis (丁 score 5-2.5) 
BMD 2-5 SD or more below the young adult mean in the 
Osteoporosis Presence of one or more fragility fractures (T score <-2-5) 
A 丁-score is defined as the number of standard deviations (SD) above or 
below the average BMD value for young healthy white women. T-score = 
(Measured BMD - young adult reference mean BMD)/ young adult reference 
SD (NIH Consensus Development Panel on Osteoporosis Prevention, 
Diagnosis, and Therapy, 2000) 
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Figure 1-1. Gradient-of-risk Relationship between Bone Density and 
Fracture Risk. Bone density is plotted in T-score units relative to the mean 
and SD of healthy young adult population. World Health Organization 
definitions of osteoporosis, osteopenia, and "normal" are intended to identify 
individuals at high, intermediate, and low risks of fracture. In this figure, a 
decrease in T-score by 1 unit increases fracture risk by a factor of 2.5. This 
approximates to relationship between hip BMD and hip-fracture risk. 
(Modified from Fogelman & Blake, 2000) 
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1.1.2 Epidemiology and outcomes 
Osteoporosis is a common disease predominantly affecting older 
people owing to age-related bone loss and microarchitectural deterioration of 
bone tissue. As the average life expectancy of world's population shifts 
rapidly upwards, the prevalence of osteoporosis rises steeply. Actually, 
osteoporosis has become a major health concern worldwide. Its associated 
fragility fractures, most frequently of the hip (proximal femur), spine (vertebral 
bodies), and wrist (distal forearm), result in significant mortality and morbidity, 
which cause substantial clinical and economic burden to society. 
1.1.2.1 Hip fractures 
Hip fractures are the most severe and devastating outcome of 
osteoporosis since they incur more deaths and disability compared with other 
type of osteoporotic fractures. Most of them require hospitalization and 
frequently lead to prolonged or permanent disability and even death. 
Previous studies have shown that nearly half of the patients with hip fractures 
do not completely recover physical functioning (Morris et a/.，2002) and 12 to 
35 percent of patients die within 12 months (Center et a/., 1999; van Staa et 
a/•，2001). As a consequence, deterioration of quality of life and substantial 
increase in health care expenditures are the results. Unfortunately, the total 
number of hip fractures and its associated cost is going to increase 
dramatically over the next fifty years. Cooper and colleagues estimates that 
the number of hip fractures will rise from 1.7 million in 1990 to 6.3 million in 
2050, with an estimated cost of $131 billion, owing to the huge increase in 
4 
Chapter 1. Introduction 
the elderly population of the world (Cooper et al” 1992a). In fact, the 
incidence of hip fractures has already been described to increase 
exponentially with age, while the combination of age-related decrease in 
BMD at the proximal femur and increase in the liability of falling mostly 
accounts for the rising trend (Looker et al., 1997; Winner et al., 1989). The 
likelihood of sustaining a hip fracture in elderly woman is approximately two 
to three times as many as observed in elderly men. This can be explained by 
the fact that women lose BMD more rapidly and experience more falls than 
men do as they age (Looker et al., 1997; van Staa et al., 2001; Winner et al., 
1989). 
1.1.2.2 Vertebral fractures 
Vertebral fractures have long been regarded as a hallmark of 
postmenopausal osteoporosis because their prevalence not only are related 
with age, but also rises dramatically after the onset of menopause (Kanis & 
Pitt, 1992). However, their epidemiology is less well characterized compared 
with hip fractures, predominantly because there are no universally accepted 
diagnostic criteria of this type of fracture, and the vast majority of which is 
asymptomatic or present just with indistinct symptoms and thereby become 
clinically undetected (Riggs & Melton, 1995). Even when vertebral 
deformities are identified on radiographs, it is estimated that only about one-
third of afflicted women come to medical attention, with less than 10 percent 
necessitating admission to hospital (Cooper et al., 1992b). Unlike hip 
fractures, most vertebral fractures are not the results of severe trauma, most 
are precipitated by routine day-to-day activities and some may even occur 
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spontaneously. Indeed, it is often overlooked that vertebral fractures are the 
most common type of osteoporotic fractures. They occur with a higher 
incidence earlier in life than other types of osteoporotic fractures and are 
associated with excessive mortality and morbidity (Meunier et a/.，1999). It is 
reported that women with at least one clinically diagnosed vertebral fracture 
have a 15 to 23 percent greater age-adjusted mortality rate than age-
matched women who do not have a fracture (Haczynski & Jakimiuk, 2001; 
van Staa et a/., 2001). In addition, vertebral fractures are associated with 
decreased physical functions, such as difficult bending, and a subsequent 
difficulty with activities of daily living (Ross, 1997). However, patients suffer 
from not only declines in physical performance, but also psychosocial 
problems including social isolation and loss of self-esteem, because of 
physical impairments and changes in appearance resulting from height loss， 
spinal deformity, abdominal protrusion, and other physical consequences of 
vertebral fractures. Many patients in the initial phases of the disease express 
substantial anxiety (Gold, 1996) and 40 percent of patients with vertebral 
compression fracture develop depression (Mazanec et al., 2003). What's 
more, vertebral fracture is also a strong indicator for subsequent fractures at 
new vertebral sites as well as other anatomical sites susceptible to 
osteoporosis (Black et al.，1999; Melton et al” 1999). It has previously been 
demonstrated that one prior vertebral fracture is associated with a four- to 
five-fold increased risk of a new vertebral fracture and four-fold increased risk 
of suffering a further non-vertebral fracture (Burger et al., 1994; Ross et al., 
1991). Unfortunately, the incidence of vertebral fractures rises rapidly with 
age in both sexes. Many studies have showed that the prevalence of 
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vertebral fractures in men is similar to, or greater than, that in women after 
the age of 50 to 60 years (Davies et a/•，1996; O'Neill et a/.， 1996). The 
gender difference may reflect a greater incidence of traumatic vertebral 
fractures in men from adolescence through middle life. Over the age of 60， 
there is a reversal of this trend with vertebral fractures becoming more 
common in women in which the incident rate is two- to three-fold greater in 
women than in men, which is in part due to the longer life expectancy of 
women, in additional to postmenopausal bone loss (Cooper et a/., 1992a; 
Sanders et al” 1998; The European Prospective Osteoporosis Study Group, 
2002). 
1.1.2.3 Wrist fractures 
Wrist fractures are the most common type of fracture in women before 
the incidences of hip and vertebral fractures rise exponentially after the onset 
of menopause (Melton, 1995; van Staa et a/., 2002). They usually occur 
when the arm is outstretched to stabilize a fall. In comparison with hip and 
vertebral fractures, wrist fractures display different patterns of age-related 
occurrence. In women, there is a steep rise in incidence after menopause, 
but instead of a continuous, exponential increase with age, the incidence 
rates reach plateau after about the age of 60 years (Melton, 1995). There 
may be an age-related increase in the susceptibility to failing and rapid 
postmenopausal bone loss，while, on the other hand, the speed and strength 
of outstretching the arm during falling decrease with age. The incidence rate 
of wrist fractures remains low in men aged 35 years or older, whereas the 
majority of wrist fractures occur in women (Melton, 1995). The age-adjusted 
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female-to-male ratio is four to one, with nearly one half occurring among 
women aged 65 years and over (Kakarlapudi et al” 2000). Generally, there is 
no excess mortality among patients who sustain wrist fractures (Browner et 
ai, 1996; Center etai, 1999). 
1.1.3 Postmenopausal osteoporosis 
Osteoporosis is more prevalent in women than in men because 
women suffer both age-related and menopause-related abnormalities in bone 
remodeling causing degradation of the material and structural properties, 
which lead to an accelerated phase of bone loss and deterioration, mainly of 
trabecular bone, at the onset of menopause. As a consequence, 
postmenopausal osteoporosis is common. 
1.1.3.1 Pathogenesis 
The pathogenesis of postmenopausal osteoporosis is not well 
understood. Yet, it is clear that this disease is a multifactorial one, which 
involves a complex interaction between genetic and environmental factors. 
The resulting bone fragility is a problem in biomechanics. Low bone mass 
and alterations in bone structure contribute to the tendency to fracture. 
Therefore, the quantitative and qualitative changes in bone material 
properties are important factors in this disease. 
8 
Chapter 1. Introduction 
(1) Bone Mass 
Bone mass is closely related to bone mechanical strength. It increases 
with age and the majority of bone mass is achieved during the first two 
decades of life. Starting around the third decade of life, after peak bone mass, 
which corresponds to the maximum amount of bony tissue present at the end 
of skeletal maturation, has been reached, there is a slow and steady loss of 
bone. In woman, around and for a few years after menopause, there is a 
phase of rapid bone loss caused by estrogen deficiency. Then the decrease 
in bone mass slows down between the ages of 60 and 70，and bone loss 
tends to accelerate again in the elderly for unrecognized reason (Cummings, 
2002). While the risk of fracture increases with decreasing bone mass, there 
are three fundamental pathogenetic mechanisms of osteoporosis: Firstly, 
failure to achieve optimal peak bone mass during skeletal growth; Secondly, 
excessive resorption of bone once peak bone mass has been achieved; and 
thirdly, impaired bone formation responses during remodeling (Raisz, 2001). 
Despite the importance of low bone mass in increased osteoporotic fracture 
incidence, fragility fractures are not solely the consequence of low bone 
mass. 
(2) Bone Architecture and Bone Mineralization 
Bone architecture and bone mineralization are also important 
determinants of bone mechanical strength. In both cortical and trabecular 
bone, within the bone matrix, the unique triple helical structure of type I 
collagen confers toughness and flexibility of bone tissue. In the mean time, 
the size and concentration of the crystals of hydroxyapatite-like minerals in 
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the triple helix of type I collagen matrix determine the stiffness of bone tissue. 
Higher mineral content increases stiffness. The harmonic combination of 
mineral crystallinity and collagen structure results in bone that is stiff and 
flexible, thus strong. During menopause, the accelerated bone remodeling 
rate with bone resorption exceeding bone formation triggered by estrogen 
deficiency causes deterioration of collagen structure, which impairs the 
architectural integrity. This, in turn, produces structural damage in the cortical 
and trabecular bones, causing cortical thinning and intracortical porosity: 
trabecular thinning, modification of trabecular shape from plates to rods, 
perforation and/or disappearance of trabeculae, loss of trabecular 
connectivity and increased trabecular bone anisotropy (Seeman, 2001). At 
the same time, there is also excessive loss of mineral from the bone matrix 
accompanied by high bone remodeling rate, which changes bone material 
properties. Mineralization of bone matrix implies two successive steps, with a 
primary rapid deposition of mineral on the calcification front followed by a 
slow and progressive process of mineral deposition，which includes an 
increase in the amount of crystals, and/or an augmentation of crystal size 
toward their maximum dimensions, known as secondary mineralization. The 
accelerated bone remodeling causes a reduction in the time available for the 
secondary mineralization, which induces hypomineralization, reducing 
stiffness (Seeman, 2002). Eventually, the deterioration of trabecular and 
cortical bone architecture and reduced bone mineralization make bone less 
able to tolerate load and more susceptible to fragility fracture. 
10 
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Modification in bone strength caused by alternations in bone quantity 
(bone mass) and bone quality (bone architecture and bone mineralization) is 
crucial to determining the osteoporotic fracture risk. Various fundamental 
factors that contribute to the disease are discussed below. 
1.1.3.1.1 Genetics 
Clinical observations reveal that genetic factors play an important role 
in regulating BMD and other determinants of osteoporotic fracture risk. Twin 
studies have suggested that 50 to 83 percent of the variance in BMD is 
genetically determined, with strongest effects in the axial skeleton (Stewart & 
Ralston, 2000). On the other hand, numerous independent family studies 
have demonstrated significant familial correlation, including sibling and 
parent-offspring correlation, for BMD. Strong heritability estimates were 
yielded even after adjusting for lifestyle factors that are known to regulate 
BMD (Krall & Dawson-Hughes, 1993). Along with these, the prevalence of 
osteoporosis has also been shown to increase among individuals with a 
positive family history of osteoporosis, reflected by the finding that lower 
BMD is associated with the presence of first degree relatives with 
osteoporotic fractures (Evans etal., 1988; Rubin etal.，1999). This can be, at 
least in part, explained by the substantial genetic contribution to peak BMD, 
which has been supported by observations that correlation of BMD between 
mothers and their younger premenopausal daughters is stronger than that 
between mothers and older post-menopausal daughters, and strong 
correlation of BMD is observed between parents and children who have not 
yet attained peak BMD (Danielson et ai, 1999; Ferrari et a/., 1998; Lonzer et 
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a/., 1996). In contrast to peak BMD, the rate of bone loss, which is also one 
of the main determinants of postmenopausal BMD, appears to be less 
genetically determined, whereas the influence of shared environment 
appears to be more important than genetic predisposition (Slemenda et a/.， 
1992). Apart from BMD, genetic influence on the liability of fracture 
independently of BMD is also evident. Several studies have demonstrated 
that there is heritable component in other determinants of osteoporotic 
fracture risk, including femoral neck geometry and hip axis length, ultrasound 
properties of bone, biochemical markers of bone remodeling, body mass 
index, muscle strength, and age at menarche and menopause (Stewart & 
Ralston, 2000). In keeping with these observations, associations between 
skeletal traits and particular genetic variants have been reported in candidate 
genes studies. Polymorphisms in the vitamin D receptor (VDR), collagen type 
I alpha 1 gene (C0LIA1), estrogen receptor (ER) alpha, transforming growth 
factor beta (TGFP), apolipoprotein E (ApoE), osteocalcin (OCL), calcitonin 
receptor (CR), alpha 2HS-glycoprotein (AHSG), parathyroid hormone (PTH), 
androgen receptor (AR), IL-6 and IL-1 receptor antagonist gene (IL-1RN) 
have been shown to be implicated in the regulation of bone mass or 
osteoporotic fractures (Table 1-2). Although the individual contribution of 
candidate genes to the pathogenesis of osteoporosis is modest, it is possible 
that the aggregate genetic profile will be clinically useful. 
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Table 1-2. Candidate Genes Study in Osteoporosis 
Candidate Function Association References  
Calcium absorption; BMD’ calcium 
VDR osteoblast-osteoclast ^Dsorpwon Morrison etal., 1992 
activity ， r u m OCL 
‘ levels 
Osteoblast-osteoclast ^KAn Sano etal., 1995 
activity Kobayashi et al.，1996 
AR Osteoblast function BMD Sowers etal., 1999 
Calcium homeostasis; 
PTH osteoblast-osteoclast BMD Hosoi etal., 1999 
activity 
PR Osteoclast function BMD, vertebral MasI et al., 1998 
CR usteociast Tunction fracture Taboulet et a/•，1998 
PPAR-Y ^ M a t i o n 瞧 Oga 一 a/., 1999 
, " ‘ • ‘ BMD, vertebral orantef a/.. 1996 
C0LIA1 Matrix component fracture; hip 
fracture 
AHSG Matrix component Heel ultrasound Zmuda et al., 1998 
OCL Matrix component BMD Dohi etal., 1998 
T � � .O s t e o b l a s t - o s t e o c l a s t 丨圆？’ vertebral Langdahi etal mj 
TGFP-1 fracture; serum Yamada et al., 1998 
acuv丨ty TGFp levels Grainger et al., 1999 
IL-6 Osteoclast activity BMD 丁 ^ = = , � 9 7棚 
丨 L-1RN 二 ； 一 e o c 丨 ast = : 一 丨 — 
ApoE Vitamin K transport BMD, hip fracture 二;: 
(Source: Stewart & Ralston, 2000) 
Abbreviations: VDR, vitamin D receptor; ER, estrogen receptor; AR, androgen receptor; PTH, 
parathyroid hormone; CR, calcitonin receptor; PPAR-y, peroxisome proliferator-activated 
receptor gamma; C0LIA1, collagen type I alpha 1 gene; AHSG, alpha 2HS-glycoprotein; 
OCL, osteocalcin; TGFp-1, transforming growth factor beta 1; IL-6, interieukin-6; IL-1RN, 
interleukin-1 receptor antagonist gene; ApoE, apolipoprotein E 
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1.1.3.1.2 Bone remodeling 
Bone remodeling is a process, which is responsible for normal 
modeling of bones during growth and repair of damage sustained by the 
skeleton throughout life. The bone remodeling cycle involves a complex 
series of sequential steps taking place in basic multicellular units (BMUs), 
where the actions of osteoblasts and osteoclasts are tightly coupled to retain 
the balance between formation and resorption of bone. Within each BMU, the 
bone remodeling cycle commences with the activation of haemopoietic 
precursors to form osteoclasts, giant multi-nucleated cells that excavate or 
resorb a cavity (Howship's lacunae) on the bone surface. Osteoclasts then 
undergo apoptosis in a brief rest period known as the reversal phase. After 
that, local mesenchymal bone marrow stem cells differentiate into 
osteoblasts, which are attached into the empty resorption pit. There they 
accumulate as clusters of plump cuboidal cells along the bone surface and 
produce proteins, both collagenous and non-collagenous, which constitute 
the matrix of newly formed bone. Then, osteoblasts are also responsible for 
calcification of the newly formed matrix (osteoid), which becomes fully 
mineralized new bone, and restore the remodeling sites to a quiescence 
phase (Figure 1-2). 
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, Bone Lining Cell 
。！ 
Osteoblast —i ；' ^ . _ ^ , ^ 
‘ Quiescence 厂 Osteoclast 
Formation ^ . . Resomtion 
Osteoid — 
L Osteocvte 
Figure 1-2. The Bone Remodeling Cycle. Bone remodeling is divided into 4 
phases: Quiescence, resorption, reversal and formation. Osteoclasts are 
responsible for bone resorption and osteoblasts are for bone formation. 
Osteocytes and bone lining cells are terminally differentiated cells, whose 
functions remain obscure. (Modified from Ralston & Kleerekoper, 2002) 
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(1) The interaction of osteoclast and osteoblast 
The close proximity in which both osteoclasts and osteoblasts are 
located within each BMU allows the interaction of osteoclast and osteoblast, 
and tight coupling of their functions. Osteoblasts play a critical role in the 
support and regulation of osteoclast differentiation. It is illustrated by the fact 
that osteotropic hormones like 1,25-dihydroxyvitamin Ds (1,25(OH)2D3) and 
PTH, local factors like prostaglandins (PGs), and inflammatory cytokines like 
IL-1, IL-6, IL-11 and tumor necrosis factor (TNF) promote osteoclastogenesis 
by inducing the production of a membrane-bound signaling protein named 
RANK ligand (RANKL) on osteoblasts/stromal cells. RANKL interacts with the 
receptor activator of nuclear factor kappa B (RANK), which is expressed on 
osteoclast precursors of haemopoietic origin. The interaction results in 
differentiation and fusion of osteoclast precursors to form active osteoclasts, 
thus increases osteoclastic activity (Suda et ai, 1999). On the other hand, 
osteoprotegerin (OPG), which is produced by a variety of cells including 
osteoblasts/stromal cells, inhibits osteoclastogenesis. It is a soluble "decoy" 
receptor, which competes with RANK for RANKL (Lacey et ai, 1998; Yasuda 
et al., 1998). The ratio of OPG to RANKL determines whether bone 
resorption is stimulated or inhibited. 
In addition to RANKL, macrophage colony stimulating factor (M-CSF) 
produced by osteoblasts/stromal cells is also a prerequisite for both 
proliferation and differentiation of osteoclast progenitors. Previous studies 
have demonstrated that it increases cytoplasmic spreading, fusion of 
osteoclastic precursors in osteoclast and osteoclastic resorption, as well as 
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prolongs the survival of osteolclasts (Amano et al., 1998; Jimi et al., 1995; 
Lees & Heersche, 1999; Sarma & Flanagan, 1996). 
The interaction between osteoclasts and osteoblasts may also be 
revealed by the possibility that osteoclasts secrete site-directing signal for 
osteoblast attachment to sites of prior bone resorption. A recent report has 
shown that osteoblasts may identify a prior resorbed surface by recognizing 
tartrate-resistant acid phosphatase (TRAP), an osteoclast lysosomal enzyme 
(Sheu et al” 2002). It is hypothesized that binding to TRAP secreted by 
osteoclast may be one mechanism by which the full osteoblast phenotype is 
expressed during the process of bone remodeling (Sheu et a/., 2003). 
(2) Estrogen 
Estrogen deficiency has been well known to be a primary pathogenetic 
factor for postmenopausal osteoporosis and estrogen is an important 
regulator of bone mass. ERs, both ERa and ERp, have been identified on 
osteoblasts and osteoclasts (Bord et al., 2001). This indicates the 
participation of estrogen in bone remodeling. Although the precise 
mechanisms by which estrogen regulates bone remodeling are not well 
understood, it is suggested that estrogen acts by altering either the 
production or activity of local factors, which regulate the differentiation and 
function of osteoblasts and osteoclasts. It inhibits the synthesis and secretion 
of the cytokines, like IL-1, IL-6, TNF-a, M-CSF and granulocyte-macrophage 
colony stimulating factor (GM-CSF), which promote osteoclastogenesis 
and/or bone resorption, from osteoblast/stromal cells and/or cells of 
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monocyte/macrophage lineage (Pacifici R.，1996), and insulin-like growth 
factor I (IGF-I), which is an autocrine enhancer of osteoblast functions 
(Turner et al., 1999; Zhao et a/.，2000). Additionally, estrogen modulates the 
production of PGs, which are mainly produced by osteoblast/stromal cells. 
PGs are multifunctional regulators with both stimulatory and inhibitory effects 
on bone formation and resorption (Wani et al., 1999; Jee & May, 1997). 
Previous studies have shown that estrogen deficiency stimulates the 
production of PEG2, which partially contributes to the accelerated 
osteoclastogenesis (Kanematsu et al” 2000; Kawaguchi et al., 1995), 
whereas estrogen enhances mechanical stress-induced PGE2 production, 
which in turn stimulates osteoblast activity and inhibites osteoclast 
recruitment (Joldersma et al., 2001). These observations suggest that 
estrogen may potentiate the anabolic effects of PGs. Besides, estrogen 
stimulates the production and release ofTGF-p, which enhances osteoblastic 
bone formation autocrinely and inhibits osteoclastic bone resorption 
(Eriebacher et al., 1998; Heino et al., 2002) and OPG, which is a protein with 
a critical role in the inhibition of the function of osteoclasts by blocking the 
RANK-RANKL interaction. While the protective effects of estrogen on the 
bone have been attributed mainly to its inhibitory actions on osteoclastic bone 
resorption, it is evident that it may also stimulate bone formation (Okazaki et 
al., 2002). After menopause, estrogen deficiency is responsible for elevated 
bone remodeling rate in which both bone resorption and formation accelerate. 
However, the increase in the rate of bone formation may be due to increased 
number of remodeling sites. Consequently, normal bone remodeling 
becomes uncoupled, the rate of resorption is so elevated that it is beyond the 
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capacity of osteoblasts to restore the original amount of bone volume, and 
bone loss is resulted. 
(3) Parathyroid hormone and 1,25-dihydroxyvitamin Ds 
PTH and 1，25(OH)2D3 (the biologically most active metabolite of 
vitamin D) are hormones, which are involved in calcium homeostasis as well 
as play a pathogenic role in age-related bone loss. Moderate vitamin D 
deficiency is quite common in older individuals especially those who do not 
venture outdoors regularly. These individuals also manifest secondary 
hyperparathyroidism, which contributes to the development of osteoporosis. 
In elderly women, hyperparathyroidism could worsen the severity of 
postmenopausal osteoporosis. 
PTH is an activator of bone remodeling. It stimulates bone resorption 
by increasing the number of osteoclasts in bone and activating mature 
osteoclasts, and increases bone formation by stimulating osteoblast 
differentiation and probably inhibiting osteoblast apoptosis (Hock, 2003). This 
stimulation of activity may be acting through the activation of parathyroid 
hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor and the 
recruitments of a number of local factors, and mediated by 
osteoblasts/stromal cells (Lanske et a/.， 1998). it is evident that increased 
bone formation predominates with intermittent PTH administration and 
increased bone resorption is enhanced with constant PTH administration 
(Kroll，2000). Undoubtedly, the mechanisms of PTH actions are complex. 
Although they have not been fully delineated, evidences have been 
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accumulating that PTH induces the production of IGF-I from osteoblasts and 
other unidentified factors, through which it exerts bone formation stimulating 
action. In addition, it is hypothesized that the anabolic actions of PTH on 
bone may require active osteociastogenesis, which is PTH-stimulated and 
mediated, at least in part, by IL-6 (Grey et ai, 1999; Rosen, 2004). 
1，25(0H)2D3 promotes osteociastogenesis and the activity of 
osteoclasts, as well as terminal differentiation of osteoblasts via VDR on 
osteoblasts/stromal cells (Guriek et ai, 2002). Although the effects of 
1’25(0H)2 on the bone are diverse and have been a matter of debate, it 
appears to enhance bone formation rather than bone resorption under 
physiological conditions. 
(4) Other regulators of bone remodeling 
The process of bone remodeling involves intricate coupling of bone 
resorption and formation, which is mediated by systemic/endocrine hormones 
and local/paracine and autocrine factors. In addition to hormones and factors 
mentioned before, hormones like growth hormone, thyroid hormone, 
glucocorticoids, PTHrP, bone morphogentic proteins, platelet-derived growth 
factors, fibroblast growth factors and vascular endothelial growth factors, and 
transcription factors, like core binding factor and osterix, are involved in 
osteoblast regulation. Hormones, like PTHrP, calcitonin, thyroid hormone, 
vitamin A and growth factors, and cytokines like IL-11, leukemia inhibitory 
factor, oncostatin M，interferon gamma, participate in osteoclast regulation. 
As listed above, there are a vast diversity of factors regulating bone formation 
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and resorption. The coordinated activities of these factors are major 
determinants of skeletal health (Hurley & Lorenzo, 2004). 
1.1.3.1.3 Calcium homeostasis 
Apart from providing structure support for muscles and internal organs, 
bone is also a reservoir for minerals and elements particularly calcium, which 
is important for providing bone infrastructure. The fact that 97 to 99 percent 
of body's calcium stores is in bone reflects the integral role of skeleton in 
calcium homeostasis. An adequate intake of calcium appears to be important 
in reducing age-related bone loss，since calcium supplements in 
postmenopausal women have been shown to decelerate bone loss (Reid et 
al.’ 1993). 
The principle organs involved in calcium homeostasis are bone, 
intestine and kidney, and hormones that are primarily responsible for the 
regulation of plasma and extracellular calcium concentrations are PTH, 
1，25(0H)2D3 and calcitonin, where PTH and 1’25(OH)2D3 are the 
predominant regulators, and calcitonin is a more minor player. The regulation 
of serum calcium concentration is a complex process that requires the 
coordinated responses of these three hormones. For instance, hypocalcemia 
increases the synthesis and release of PTH and inhibits the release of 
calcitonin. PTH in turn restores plasma calcium by decreasing renal tubular 
reabsorption of serum inorganic phosphate and increasing that of calcium, 
increasing the number and bone resorption activity of osteoclasts, and 
increasing renal 1’25(OH)2D3 production. 1,25(OH)2D3 increases duodenal 
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absorption and renal tubular reabsorption of calcium. As a feedback inhibitor, 
it also reduces PTH level. Hypercalcemia, in contrast, results in the synthesis 
and release of calcitonin and suppresses the release of PTH and the 
formation of 1,25(OH)2D3. Calcitonin transiently inhibits osteoclast-medicated 
bone resorption. It also inhibits renal tubular reabsorption of calcium resulting 
in increased renal calcium excretion (Figure 1-3). 
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Figure 1-3. Hormonal Control of Calcium Homeostasis. Calcium 
homeostasis is regulated by three hormones: PTH, 1，25(OH)2D3 and 
Calcitonin. Their target organs are bone, duodenum and kidney. PTH and 
1,25(0H)2D3 stimulate calcium release from bone, calcium absorption in the 
duodenum and calcium reabsorption in the kidney in order to increase 
calcium concentration in ECF, whereas calcitonin inhibits bone resorption 
and increase renal calcium excretion causing a fall in extracellular calcium 
level. 
Abbreviations: Ca^ *, calcium ion; ECF, extracellular fluid; 1, 25(OH)2D3, 1,25-
DIHYDROXYVITAMIN D3； 25(OH)2D3, 25-HYDROXYVLTAMIN D3； PTH, PARATHYROID HORMONE 
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It is obvious that sufficient calcium absorption from the intestine and 
calcium reabsorption from the kidney are important for skeletal health. As 
mentioned before, 1，25(OH)2D3 is a major regulator of calcium absorption 
and reabsorption. It is synthesized from its precursor 25-hydroxyvitamin D3 
(25(0H)D3) by the renal cytochrome P450 enzyme 25-hydroxyvitamin D3-
1 alpha-hydroxylase (1a-0Hase) and interacts with the VDR in target organs, 
which induces the production of epithelial calcium channels, TRPV5 and 
TRPV6, and intracellular calcium binding protein, calbindin (Figure 1-4). 
Calbindin is believed to be involved in the ATP-dependent transcellular 
calcium transport in the epithelia of the intestine and renal distal tubules， 
where it serves as buffer proteins that prevent intracellular free calcium ion 
concentrations from reaching toxic levels in calcium transporting cells (Gross 
& Kumar, 1990). There are two classes of calbindin: calbindin-D9K (CaBP-
D9k) expressed primarily in mammalian duodenum, and calbindin-D28K 
(CaBP-D28K) expressed highly in mammalian kidney (Christakos et al” 
2003). In the duodenum, the level of CaBP-D9K in mucosa has been shown 
to be positively correlated with 1，25(OH)2D3 level and suppressed by 
increased plasma calcium concentration (Hemmingsen et al., 2002). Renal 
CaBP-D28K level, similar to duodenal CaBP-D9K, responses to changes in 
1，25(0H)2D3 concentrations, but to a lesser extent (Hemmingsen et al., 
2002). It also increases with dietary calcium intake (Hoenderop et al., 2002). 
Moreover, it is stimulated by PTH as well as estrogen by mechanisms 
independent of changes in 1，25(OH)2D3 (Criddle et al., 1997; Hemmingsen et 
a/.，1996). These evidences indicate CaBP-D9K and CaBP-D28k play a 
significant role in calcium absorption and reabsorption respectively. 
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Figure 1-4. The Facilitated Diffusion Model of Vitamin D-mediated 
Intestinal Calciunrf Absorption and Renal Resorption. Transcellular Ca2+ 
transport takes place in the duodenum and kidney, and is a three-step-
process. Following entry of Ca2+ through the (hetero)tetrameric epithelial 
Ca2+ channels, TRPV5 (red) and TRPV6 (blue), cytosolic Ca?. is buffered by 
calbindin. At the basolateral membrane，Ca?. is extruded via a plasma 
membrane Ca2+-ATPase (PMCAlb) and a sodium-calcium-exchanger 
(NCX1). 1’25(0H)2D3 induces the transcriptions of epithelial Ca "^" channels, 
TRPV5 and TRPV6, and calbindin. (Modified from Hoenderop et al., 2003) 
Abbreviations: ADP, adenosine diphosphaie; ATP, adenosine triphosphate; Ca^ ,^ calcium 
ion; Na+, sodium ion; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3； VDR, vitamin D receptor 
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There are age-related and menopause-related declines in calcium 
absorption and impaired adaptation to a low calcium diet, which are 
correlated with abnormalities of the vitamin D-endocrine system including 
secondary hyperparathyroidism, intestinal resistance to 1’25(OH)2D3 action 
and reduced 1，25(OH)2D3 production owing to impaired 1a-0Hase activity 
(Riggs, 2003). These changes have been implicated in the pathogenesis of 
postmenopausal osteoporosis (Bell & Jackson, 1995). Along with these 
findings, numerous studies support the concept that improvements in calcium 
balance prevent bone loss and fracture, and rule out that calcium 
supplementation and hormonal therapy may reduce fracture risk primarily via 
effects on calcium homeostasis in which increasing calcium absorption and 
reabsorption in the duodenum and kidney are of vital importance in improving 
calcium extracellular balance. 
1.1.3.1.4 Life style 一 nutrition and exercise 
Nutrition is an important factor in the attainment of peak bone mass 
and maintaining skeletal health during adulthood. Calcium is one of those 
favoring bone growth and preservation throughout life. An adequate calcium 
intake, especially during growth and adolescence, has been shown to be 
associated with greater peak bone mass, slower bone loss in elderly and 
fewer fractures in various studies (Flynn, 2003). Combined supplementation 
of calcium and vitamin D, which increases calcium absorption and resorption, 
has been shown to be pharmacologically active (particularly in patients with 
dietary deficiencies), safe, and effective for the prevention and treatment of 
osteoporotic fractures (Boonen et al” 2004). Besides, decreased sodium 
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intake, increased potassium intake, and higher consumption of fresh fruits 
and vegetables are likely to be beneficial to skeletal health (Prentice, 2004). 
In contrast, smoking and chronic alcoholics increase the risk of osteoporosis 
(Ralston & Kleerekoper, 2002). 
Immobility causes substantial bone loss, whereas exercise increases 
bone mass, despite the relatively smaller gains in bone mass achieved 
during adulthood. Regular exercise, particularly weight-bearing exercise, 
contributes to the higher peak bone mass during young adulthood and 
subsequence better bone mass maintenance. Moreover, not only improving 
skeletal health, exercise also increases muscle strength, coordination, 
balance, flexibility and leads to better overall health, which further reduces 
osteoporotic fracture risk (Kai et al., 2003). 
1.1.3.2 Current pharmacological treatment 
1.1.3.2.1 Introduction 
Pharmacological therapies that effectively reduce fracture risk by 
improving bone mass are now available widely around the world. Most 
current agents inhibit bone loss by reducing bone resorption, while some may 
even increase bone mass by directly promoting bone formation. The 
bisphosphonates (alendronate and risedronate), calcitonin, estrogens and 
raloxifene are classified as anti-resorptive medications, whereas PTH is 
bone-forming medications. Calcium and vitamin D/vitamin D metabolites in 
combination increase the bioavailability of calcium and are thereby always 
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given as a baseline treatment for osteoporosis. Combination therapies 
including bisphosphonates plus estrogen, raloxifene/PTH plus 
bisphosphonates, and PTH plus estrogen have been evaluated in clinical 
studies that, generally speaking, combination therapies have resulted in the 
increases in BMD slightly over that observed with either drug was used alone 
(Maalouf et al., 2003). Nevertheless, no study on combination therapy for 
osteoporosis has shown fracture-reduction data when compared with single 
drug administration. Despite that, single drug alone is already effective in 
preventing fracture. 
(1) Bisphosphonates 
Alendronate and residronate, which are bisphosphonates, are 
effective in reducing the risks of hip and vertebral fractures in osteoporotic 
patients (Cummings et al., 1998; McClung et al., 2001). Multiple studies has 
revealed that they also prevent further fractures in women with 
postmenopausal osteoporosis and prior vertebral fractures (Black et al., 1996; 
Reginster et al., 2000). Treatment with bisphosphonates reduces bone 
resorption markers and increases BMD. 
(2) Selective estrogen-receptor modulators 
The selective estrogen receptor modulator (SERM) raloxifene has 
been shown to reduce the risk of vertebral fracture (Delmas et al., 2002)，but 
without significant effect on non-vertebral fractures in most studies of 
postmenopausal osteoporosis (Ettinger et al., 1999). Nevertheless, one 
recent study demonstrated that raloxifene decreased non-vertebral fracture 
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risk in women with severe vertebral fractures (Delmas et al., 2003). It has 
also been shown to increase BMD in postmenopausal women (Delmas et al., 
1997). In additional to providing bone protection, raloxifene also diminishes 
breast cancer risk as well as lowers total cholesterol and low-density 
lipoprotein cholesterol levels (Cauley et al., 2001; Delmas et al., 1997). 
However, it is associated with venous thromboembolism and a higher 
occurrence of hot flashes. 
(3) Hormone replacement therapy 
Estrogen replacement therapy increases BMD by inhibition of bone 
resorption (The Writing Group for the PEPI, 1996). Estrogen-plus-progestin 
therapy reduces the risks of clinical vertebral and hip fractures as well as 
increases BMD in postmenopausal women (Cauley et al., 2003). However, 
the use of combined estrogen plus progestin is associated with increased risk 
of myocardial infarction, stroke, invasive breast cancer, pulmonary embolism 
and deep vein thrombosis (Rossouw et al., 2002). 
(4) Parathyroid hormone 
PTH, which is the only anabolic agent activating bone remodeling 
units leading to enhancement in bone formation over bone resorption, 
increases BMD as well as reduces the risks of both vertebral and non-
vertebral fractures in women with postmenopausal osteoporosis (Neer et al., 
2001). 
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(5) Strontium ranelate 
Strontium ranelate increases collagenous and non-collagenous protein 
synthesis by mature osteoblast-enriched cells and suppresses preosteoclast 
differentiation. As expected, it increases BMD and reduces the risks of 
vertebral and non-vertebral fractures (Reginster et al., 2004). 
(6) Calcitonin 
Calcitonin reduces bone resorption by direct inhibition of osteoclast 
activity. Findings of a small placebo-controlled study on elderly women with 
moderate osteoporosis suggest that calcitonin increases BMD and reduces 
the risks of vertebral and peripheral fractures (Overgaard etal., 1992). 
(7) Calcium and vitamin D/vitamin D metabolite 
Inadequate dietary intake of calcium and vitamin D may contribute to 
the high prevalence of osteoporosis among elderly people. Dietary 
supplementation with calcium and vitamin D/vitamin D3 (cholecalciferol) has 
been shown to moderately reduce bone loss and the incidence of 
osteoporotic fractures including vertebral and hip fractures (Chapuy et al., 
1992; Chevalley et al., 1994; Dawson-Hughes et al., 1997). Calcium 
supplement alone has been showed to reduce bone loss and produce small 
reduction in the frequency of fractures in postmenopausal women, as well as 
prevent vertebral fracture in those with prior spine fractures (Reid et al., 1995; 
Recker et al., 1996). Conversely, vitamin D supplement has no effect on the 
incidences of hip fractures and other peripheral fractures in elderly people 
with low calcium intake (868mg/day on average) (Lips etal” 1996). The main 
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hormonal forms of vitamin D 一 1,25(OH)2D3 (calcitriol) and lalpha-
hydroxyvitamin D3 (alphacalcidol) induce a small increase in BMD, which 
seems to be limited to the spine (Gallagher et al” 2001)，and the data on the 
effects on fracture reduction are scare and conflicting. Calcium supplement is 
recommended to individuals with insufficient calcium intake. Vitamin D should 
be considered in institutionized elderly people because a high prevalence of 
vitamin D deficiency is related to low vitamin D intake, low sunshine exposure 
and impaired vitamin D synthesis in the skin (Delmas, 2002). 
1.1.3.2.2 Limitations 
In addition to the high cost of pharmacological treatments (with 
exception to the combination of calcium and vitamin D) that probably 
exceeds the economic resources of many patients, most drugs given to treat 
osteoporosis pose some difficulties in the long-term care because they may 
be contraindicated for use in sedentary patients, may have intolerable side 
effects, or may be logically difficult to administer (Table 1-3) (Dore & Hurley, 
2002). For instant, long-term treatment with raloxifene, which is a SERM that 
produces estrogen-agonistic effects on bone, may result in deteriorated 
quality of life by inducing leg cramps and increasing hot flashes. Furthermore, 
it increases the risk of venous thromboembolic events (VTEs) and should be 
discontinued during prolonged immobilization such as postsurgical recovery, 
prolonged bed rest. In view of this, future approaches to pharmacological 
treatment should look forward to further development of currently available 
medications, as well as discovery of new treatment regimes that are effective, 
safe with little side effects, and affordable to most people. 
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Table 1-3. Limitations Relating to Drug Therapy in LTC Facilities 
Estrogen 
Coronary Heart Disease: No Secondary Prevention 
QOL: Breast Tenderness, Uterine Bleeding 
Cancer: Increased Risk of Breast, Uterine Cancer 
Other Risks: VTEs; Immobility Precludes use 
Raloxifene 
QOL: Leg Cramps, Increase in Hot Flashes; Nasal Irritation 
Risks: Increased Risk of VTEs; Immobility Precludes Use 
Calcitonin 
QOL: Nasal Irritation 
iMendronate 
Contraindications: Achalasia 
QOL: Inconvenient Administration; Some Patients are Intolerant to Gl 
Side Effects 
Risedronate 
QOL: Inconvenient Administration; Some Patients are Intolerant to Gl 
Side Effects 
(Modified from Dore & Hurley, 2002) 
Abbreviations: LTC, long-term care; QOL, quality of life; VTEs, venous thromboembolic 
events; Gl, gastrointestinal 
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1.2 Traditional Chinese medicine 
1.2.1 The Kidney 
in traditional Chinese medicine (丁C M ) , the Kidney is not limited to the 
organ kidney itself; it also encompasses the urinary system, balance of 
mineral electrolytes as well as the entire endocrine system including PGs and 
the various neurotransmitters. 
The Kidney has a vast diversity of functions. They include storing the 
Essence (Jing), which is partly inherited from parents; the production of the 
Marrow to fill the brain and spinal chord as well as control the Bones; 
coupling with the Bladder (urinary bladder) to govern water metabolism, 
which refers to the transformation and transportation of body fluids; opening 
to the Ears and controlling urethra and anus, all of which are the orifices of 
the Kidney; manifesting on the head hair; and housing the Willpower (Zhi), 
which includes concepts of staying power and motivation. 
1.2.2 Kidney-tonifying herbs 
As the Kidney dominates the Bones, bone health is determined by the 
Kidney network. Scientific researches go along with the TCM theory that 
Kidney-tonifying herbs improve skeleton health. Numerous studies have 
shown that various Kidney-tonifying herbal formulae reduced bone loss in 
human with primary osteoporosis (Xie et al., 2000)，and in rats with various 
types of osteoporosis including osteoporosis resulted from aging and induced 
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by glucocorticoids (Su et al., 2002; Zhang et al., 1999). On the basis of these 
findings, three Kidney-tonifying herbs, which are commonly present in the 
traditional kidney-tonifying herbal formula, were chosen by the experts in the 
TCM field in our team as the potential agents beneficial to postmenopausal 
osteoporosis. They are Herba Epimedii, Fructus Ligustri Lucidi and Fructus 
Psoraleae. 
Herba Epimedii (Epimedium; Common name Yin Yang Huo; Horny 
Goat Weed) refers to the dried aerial parts of five Epimedium species, 
Epimedium brevicomu Maxim., E. sagittatum (Sieb. et Zucc.) Maxim., E. 
pubesce门s Maxim., E. wushanense T. S. Ying and E. koreanum Nakai. Its 
major chemical ingredients are icariin，des-o-methylicariine, p-anhydroicaritin 
and magnoflorine (Chang & But, 1986). 
Fructus Ligustri Lucidi (Ligustrum] Common name Nu Zhen Zi) refers 
to the dried fruit of Ligustrum lucidum Ai t . Its major chemical ingredients are 
oieanolic acid, acetyloleanolic acid, betulin, lupeol’ salidroside, mannitol, 
oleic acid, linolenic acid and palmitic acid (Chang & But, 1986). 
Fructus Psoraleae (Psoralea： Common name Bu Gu Zhi) refers to 
the dried fruit of Psoralea corylifolia L . Its major chemical ingredients are 
flavonoids such as bavachin, isobavachalcone, bavachromene and 
neobavachalcone, coumarins, psoralen, isopsoralen, psoralidin, isopsoralidin, 
corylidin, bakuchiol, volatile oil, fixed oil, and resin (Chang & But, 1986). 
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Figure 1-5. Photographs of Herba Epimedii, Fructus Ligustri Lucidi and 
Fructus Psoraleae used in the present studies. (A) Herba Epimedii•，(B) 
Fructus Ligustri Lucidi•，(C) Fructus Psoraleae 
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1.3 Aim of the studies 
The aim of the present studies was to investigate the effects of the 
aqueous and ethanol extracts of a Kidney-tonifying herbal formula ELP, 
which composed of Herba Epimedii (Epimedium), Fructus Ligustri Lucidi 
(Ligustrum) and Fructus Psoraleae (Psoralea), and its two major ingredients 
Epimedium and Ligustrum on bone metabolism and calcium homeostasis. 
Ovariectomized adult Sprague-Dawley rats were recruited as the animal 
model of postmenopausal osteoporosis. The safety of the herbal extracts 
was assessed by monitoring body weight and uterine wet weight. The effects 
of the extracts of these herbs and herbal formula on bone health were 
studied by monitoring the changes of BMD in the lumbar spine of these 
ovariectomized rats with/without herbal extract-feeding and in sham-operated 
rats. Meanwhile, the effects of the herbal extracts on calcium homeostasis 
were also investigated. Calcium absorption was monitored by measuring the 
duodenal gene expression levels of VDR and CaBP-D9K, and calcium 
reabsorption was monitored by measuring the renal mRNA levels of VDR 
and CaBP-D28K. In addition, the renal mRNA expression of 1a-0Hase， 
which plays an indispensable role in calcium homeostasis by catalyzing 
synthesis of 1,25(OH)2D3，was also examined. 
Besides, the actions of the herbal extracts on bone formation were tested 
on rat osteoblast-like osteosarcoma cell line, UMR-106. The cell proliferation 
was measured by MTT assay, and osteoblastic differentiation was detected 
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by measuring cellular alkaline phosphatase activity and the degree of matrix 
mineralization. 
Last but not least， competitive estrogen receptor binding assay was 
performed using human breast cancer MCF-7 cell line, which expresses 
estrogen receptor, to investigate whether the components of the herbal 
extracts bind estrogen receptor. 
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2.1 Kidney-tonifying herbs and herbal formula 
2.1.1 Sources 
The Kidney-tonifying herbal formula, ELP, which was composed of 
Herba Epimedii (Epimedium), Fructus Ligustri Lucidi (Ligustrum) and Fructus 
Psoraleae (Psoralea) in a ratio of 5:4:1 (w/w), was designed and examined in 
the present studies. In addition, two of its ingredients, Epimedium and 
Ligustrum were also tested. All herbs were purchased from a reliable herb 
supplier in dried forms (Figure 1-5). In the present studies, Epimedium used 
was a mixture of aerial parts of the two source plants, Epimedium 
leptorrhizum Steam and Epimedium wushanense T. S. Ying (Voucher 
Specimen No: ICM-2004-2547), whilst Ligustrum and Psoralea used were 
the dried fruits of Ligustrum lucidum Ait. (Voucher Specimen No: ICM-2004-
2566) and Psoralea corylifolia L (Voucher Specimen No: ICM-2004-2568) 
respectively. 
2.1.2 Herbal extract preparation 
ELP, Epimedium and Ligustrum were subjected to extraction with 
distilled water and 70% (v/v) ethanol. Dried herbs were refluxed with distilled 
water or 70% ethanol for two hours twice. The solution was collected and left 
overnight at room temperature. The residue was removed by filtration 
through a piece of absorbent gauze. The filtrate was then concentrated under 
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reduced pressure at 40°C, and lyophilized on FreezeMobile Freeze dryer 
(Virtis, Gardiner, New York). The resulting powders were stored at 
-20X . 
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2.2 Animal study 
2.2.1 Reagents 
Raloxifene referred as Evista film coated tablet, which contained 
raloxifene hydrochloride and the producer was Eli Lilly and Company 
(Basingstoke, England). Ethidium bromide (10mg/ml)，MgCb (50mM), 
random primer (3[jg/Ml) and Trizol Reagent were from Invitrogen (Carlsbad, 
CA). Oligo (dT)25 was custom-synthesized by Invitrogen Japan (Tokyo, 
Japan). DEPC solution was from Sigma-Aldrich (St. Louis, MO). The 
modified diet containing 0.1% calcium and 0.3% phosphate was from Glen 
Forrest Stockfeeders (Glen Forrest, Western Australia). 5X M-MuLV reverse 
transcriptase reaction buffer and M-MuLV reverse transcriptase RNase H 
minus (250U/|jl) were generous gifts from Prof. PC Shaw (The Chinese 
University of Hong Kong, Hong Kong). 2X TaqMan Universal PGR master 
mix and 20X Assays-on-Demand gene expression products (consisting of 
forward and reverse PGR primers and 1 FAM dye-labeled TaqMan MGB 
probe) were from Applied Biosystems (Foster City, CA). Taq PGR nucleotide 
mix (10mM) was from Promega (Madison, Wl). 
2.2.2 Animal care 
Six-month-old female Sprague-Dawley retired breeder rats were 
purchased from the Laboratory Animal Services Center, The Chinese 
University of Hong Kong, Hong Kong. They were housed five per cage in 
stainless steel cages with free access to distilled water and food. 
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Temperature was maintained at 25�C and humidity was constant. Rats were 
kept under a 12-hour light-dark cycle. 
2.2.3 Herbs and herbal formula preparations for animal studies 
In this study, the aqueous and ethanol extracts of ELP and its two 
major ingredients, Epimedium and Ligustrum, were tested. However, the 
aqueous and ethanol extracts of Psoralea, which was also the remaining 
ingredient of ELP, were not tested owing to limited manpower. Different 
concentrations of the herbal extracts were prepared by dissolving the 
lyophilized powers in distilled water and mixed by vortexing. They were 
prepared freshly every day. 
2.2.4 Experimental design 
starting from six months of age, rats were kept in the conditions as 
described in Section 2.2.2. At the age of eleven months, rats were randomly 
assigned to one of the nine treatment groups: (1) sham (n=9), (2) control 
(n=10)，(3) aqueous extract of Epimedium (Epi-H20; n=10), (4) ethanol 
extract of Epimedium (Epi-EtOH; n=10), (5) aqueous extract of Ligustrum 
(Lig-H20; n=9), (6) ethanol extract of Ligustrum (Lig-EtOH; n=7)，(7) aqueous 
extract of ELP (ELP-H20; n=9), (8) ethanol extract of ELP (ELP-EtOH; n=8) 
and (9) raloxifene (n=9) groups. Except the sham group, in which 
ovariectomy was sham operated, the other eight groups of rats were 
bilaterally ovariectomized (OVX) under intraperitoneal anesthesia with a 
cocktail of ketamine and xylazine (2\i\/g body weight; ketamine: xylazine: 
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water = 3: 2: 3). 17g of a modified diet containing 0.1% calcium and 0.3% 
phosphorus were supplied per cage daily (Table 2-1). Distilled water was 
freely available. 
Treatment started 3 weeks after surgery, when the ovariectomized 
rats were considered at the state of postmenopausal osteoporosis, and 
lasted for 18 weeks. For all herb or herbal formula treatment groups, herbal 
extracts were dissolved in distilled water and 2ml decoction (0.35g/ml) was 
administrated daily to each rat. In the herbal formula treatment groups, the 
dosages were reduced to 0.175g/ml after one month of administration due to 
practical reasons. In the raloxifene group, rats received 2ml of raloxifene 
(1mg/ml) daily. The administrations of treatments were achieved by oral 
gavages. In the control and sham groups, rats were gavaged orally with 2ml 
distilled water daily. 
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Table 2-1. Composition of the Experimental Diet 
Diet Composition 
Sucrose 10% 
Wheat Starch 41.6% 
Dextrin 13.2% 
Cellulose 5% 
Casein (Acid) 20% 
Canola Oil 7% 
Methionine 0.3% 
Choline Chloride 0.25% 
AIN93M Vitamins 1% 
AIN93M Trace Minerals 0.14% 
Calcium Carbonate 0.24% 
Sodium Chloride 0.26% 
Pottasium DiHyd Phosphate 0.68% 
Pottasium Citrate 0.25% 
The diet was purchased from Glen Forrest Stockfeeders (Glen Forrest, 
Western Australia). It is based on AIN93G specifications. The calcium 
content is 0.1g/100g and the phosphorous content is 0.3g/100g. 
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2.2.5 Gene expression study 
2.2.5.1 Tissue preparation 
At the end of the treatment period, rats were sacrificed by decapitation. 
Duodenal segments and the left kidneys were then removed rapidly for RNA 
isolation. 
For the duodenums, the proximal 10 cm of the duodenums were 
removed and immersed in ice-cold PBS for less than 1 minute. They were 
then flushed clean with ice-cold PBS using syringe and needle for three times. 
On an ice-cold platform, which was made up of an inverted glass petri dish 
placed on ice, the duodenums were cut open. The mucosa was scraped from 
underlying coats with a chilled glass slide and immediately homogenized in 
5ml of Trizol Reagent on ice with a blade homogenizer. The Trizol 
homogenates were stored at -70°C. 
For the kidneys, the capsules were peeled off, and the whole kidneys 
were placed in aluminum foil packages and frozen in liquid nitrogen. The 
kidneys were broken into tiny pieces by a hammer. Approximately 0.2mg of 
the kidneys was pulverized with the mortar and pestle under liquid nitrogen. 
The kidney powders were suspended in 3ml of Trizol Reagent. The Trizol 
homogenates were stored at -70°C. 
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2.2.5.2 Isolation of total RNA 
Total RNA was prepared from Trizol homogenates as recommended 
by the manufacturer. Trizol homogenates were centrifuged at 4000xg for 25 
minutes at 4°C. The supernatants were transferred to fresh eppendrofs and 
incubated at room temperature for 5 minutes. For every 1ml of Trizol 
homogenates, 0.2ml chloroform was added. Eppendrofs were shaken 
vigorously by hand for 15 seconds and then incubated at room temperature 
for 3 minutes. Samples were centrifuged at 11900xg for 15 minutes at 4�C. 
Following centrifugation, the mixture separated into a lower red, phenol-
chloroform phase, an interphase, and a colorless upper aqueous phase. The 
aqueous phase, which contained RNA, was transferred to a new eppendrof. 
For every 1ml of Trizol homogenates initially present, 500|jl isopropyl ethanol 
was added. The eppendrofs were gently inverted for three times to mix the 
contents and incubated at room temperature for 10 minutes. After that, 
samples were centrifuged at 11900xg for 10 minutes at 4�C. The 
supernatants were removed and the RNA pellets remained in the bottoms of 
eppendrofs. For every 1ml of Trizol homogenates initially present, 1ml of 
75% (v/v) ethanol was added. The samples were mixed by vortexing and 
centrifuged at 7500xg for 5 minutes at 4�C. 75% Ethanol was removed and 
the RNA pellets were dried briefly in 55°C incubator for 15-20 minutes. They 
were then redissolved in 30|jl DEPC-treated water, which was prepared by 
stirring 0.1% (v/v) of diethyl pyrocarbonate (DEPC) solution in distilled water 
overnight at room temperature and then autoclaved. RNA samples were 
stored at -70X . 
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Ultraviolet absorbance spectroscopy was used to measure the 
concentration and purity of RNA. 2|jl RNA samples were dissolved in 198|jI 
5X TNE buffer (SOmM Tris-HCI, pH7.4, 1M NaCI, 5mM EDTA) and the 
absorbance was measured with Fluostar Optima Microplate Reader and 
Fluostar Optima software Version 1.30-0. The RNA concentration was 
determined by measuring the absorbance at 260nm (A260) against blank, 
which was 5X TNE buffer. The absorption of 1 OD at 260nm is equivalent to 
40|jg/ml RNA. Thus, the RNA concentration was calculated as following: 
RNA concentration (|jg/|jl) = A260 x 40/1000 x dilution factor 
The protein content was determined by measuring the absorbance at 
280nm (A280) against blank. The ratio A260/A280 was used to estimate the 
purity of RNA. The ratio between 1.8 and 2.1 indicates high purity RNA 
preparation. 
The integrity and quality of total RNA could be assessed in native 
agarose gel electrophoresis by inspection of the 28S and 18S rRNA bands. 
2|ji RNA samples were mixed with equal volume of 2X RNA loading dye and 
run on a 1% (w/v) agarose-TBE (89mM Tris-base, 89mM Boric acid and 
2mM EDTA) gel containing 0.5mg/ml ethidium bromide. The rRNA bands 
were visualized with ChemiDoc EQ system and Quantity One software 
Version 4.4.1 (Bio-Rad Laboratories, Segrate, Italy). For intact total RNA, the 
ratio between 28S and 18S rRNA bands was 2:1 and bands were sharp and 
clear. 
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2.2.5.3 Complementary DNA synthesis 
Total RNA was converted to complementary DNA (cDNA) by reverse 
transcriptase. 4|jg Total RNA was mixed with 1|jl of 50|jM oligo (dT)25，1|Jl of 
3pg/|jl random primers, 2|jl of 10mM dNTP mixture and the volume was 
brought to 12|jl with DEPC-treated water. The mixture was incubated at 65�C 
for 5 minutes and then placed on ice. 4|jl of 5X M-MuLV reverse 
transcriptase reaction buffer, 1|jl of 50mM MgCb, ^[i\ M-MuLV reverse 
transcriptase RNase H minus ( 2 5 0 _ ) and 2[i\ DEPC-treated water were 
added to the mixture. The samples were transferred to the iCycler Thermal 
Cycler 96 with iCycler software Version 3.021 (Bio-Rad Laboratories, Hemel 
Hempstead, England), which had been preheated to 25�C, and incubated for 
10 minutes followed by 50�C for 90 minutes. They were then incubated at 
8 5 � C for 5 minutes. The cDNA synthesized was stored at -20�C. 
2.2.5.4 Real-time polymerase chain reaction analysis 
Real-time polymerase chain reaction (PGR) was performed using the 
ABI Prism 7700 sequence detection system (Perkin-日mer Applied 
Biosystems, Foster City, CA). Before the PGR reactions, cDNA was diluted 
100-fold for the amplifications of p-actin (GenBank accession number 
NM_031144), CaBP-D9K (GenBank accession number NM一012521)，CaBP-
D28K (GenBank accession number NM_031984) and VDR (GenBank 
accession number NM_017058), and diluted 4-fold for the amplification of 1a-
OHase (GenBank accession number NM一053763). For cDNA prepared from 
the duodenum, the gene expressions of CaBD-D9K and VDR were studied. 
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For cDNA prepared from the kidney, the gene expressions of CaBD-D28K, 
VDR and loOHase were studied. The expressions of target genes were 
normalized with that of p-actin, which was a housekeeping gene and served 
as an internal control. The primers and probes were predesigned by Applied 
Biosystems. 
For each PGR run, a 20^1 master mixture, containing 10|jl of 2X 
TaqMan Universal PGR Master Mix, 5|jl diluted cDNA, 1|jl of 20X Assays-on-
Demand Gene Expression Products (consisting of forward and reverse PGR 
primers, and 1 FAM dye-labeled TaqMan MGB probe) and 4|j| autoclaved 
distilled water, was prepared on ice. Thermal cycling conditions comprised 
initial incubation at 50 °C for 2 minutes and then denaturation at 95°C for 10 
minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
The reactions were performed on the ABI Prism 7700 sequence detector 
(Perkin-日mer Applied Biosystems). Fluorescence measurements were 
recorded during each annealing step. At the end of each PGR run, the data 
were analyzed by the Sequence Detection System software Version 1.9.1 
(Perkin-Elmer Applied Biosystems) and amplification plots were obtained. 
The threshold was positioned to the middle one-third of the visible part 
of the exponential phase in amplification plots. Threshold cycle (Ct) values 
were exported into a Microsoft Excel worksheet for the calculation of gene 
expression according to the AACt method (Applied Biosystems). Levels of 
gene expressions in the treatment groups were presented with respect to that 
of the control group as treatment/control ratios. 
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2.3 Cell culture study 
2.3.1 Reagents 
The rat osteosarcoma cell line, UMR-106, and the human breast 
cancer cells line, MCF-7 were purchased from American Type Culture 
Collection (Manassas, VA). DMEM, fetal bovine serum, phosphate-buffered 
saline, penicillin and streptomycin, RPMI 106 and trypsin-EDTA solution 
(0.25% Trypsin, 1mM EDTA 4Na) were from Gibco BRL, Invitrogen (Grand 
Island, NY). Alizarin red S, Alkaline Phosphatase Kit, 3-[4,5 dimethylthiazol 2-
yl]-2,5-diphenyltetrazolium bromide, 17p-estradiol, Multi-Enzyme LIN-TROL 
and phenol red-free RPMI were from Sigma-Aldrich (St. Louis, MO). Bio-Rad 
Protein Assay Dye Reagent Concentrate and bovine serum albumin were 
from Bio-Rad Laboratories (Hercules, CA). Charcoal/Dextran treated FBS 
was from Hyclone (Logan, UT) and [2,4,6,7-^H(N)]estradiol (71Ci/mmol) was 
from New England Nuclear (Boston, MA). 
2.3.2 Cell lines 
2.3.2.1 Rat osteosarcoma cell line, UMR-106 
The UMR-106 cell line was derived from a transplantable rat 
osteosarcoma that had been induced by injection of radiophosphorous f p ) . 
Ceils were routinely maintained in DMEM containing 10% (v/v) heat 
inactivated fetal bovine serum (FBS), penicillin (100U/ml) and streptomycin 
(100pg/ml) in a humidified 5% CO2 atmosphere at 37�C. 
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2.3.2.2 Human breast cancer cell line, MCF-7 
The MCF-7 cell line was originally established from pleural effusion of 
a patient with breast carcinoma (Soule et al., 1973). Cells were routinely 
maintained in RPMI 1640 containing 10% (v/v) heat inactivated FBS, 
penicillin (100U/ml) and streptomycin (100|jg/ml) in a humidified 5% CO2 
atmosphere at 37�C. 
2.3.2.3 Cell culture techniques 
All cell cultures were maintained in 10ml medium containing heat 
inactivated FBS, penicillin and streptomycin, in 75cm^ tissue culture flasks 
and in a humidified 5% CO2 atmosphere at 37�C. They grew adherent to the 
ground of the flasks. The medium was replenished every 2-3 days. For 
passage of ceil lines, 80% - 90% confluent cells were rinsed with PBS, and 
then incubated with 2ml trypsin-EDTA solution in a humidified 5% CO2 
atmosphere at 37�C for 5 minutes. After detachment from the flask's ground, 
cells were harvested in 10ml fresh medium. The cells were then pelleted at 
800xg for 3 minutes. The supernatants were removed and the cells were 
resuspended in 5ml fresh medium. 500|JI aliquots of cell suspension was 
then seeded in new 75cm^ tissue culture flasks containing 10ml fresh 
medium. 
For storage, 80% - 90% confluent cells in 75cm^ tissue culture flasks 
were rinsed with 5ml PBS and trypsinized. After centrifugation, the 
supernatant was removed and cells were resuspended in 3 ml chilled 
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freezing medium containing 90% media and 10% DMSO. 1ml aliquots of cell 
suspension were then transferred to 2ml cryogenic vials (Corning, NY, 
Canada). Cells were then kept at 4 � C for 1 hour, -20�C for 1 hour, -70�C for 1 
hour and finally stored in liquid nitrogen (-196X). 
For maintenance, cells were thawed from the frozen stocks routinely 
by incubating vials of frozen cells in 37°C water bath until they just melted. 
1ml aliquot of cell suspension was then transferred to two of 75cm^ tissue 
culture flasks each containing 10ml medium. The medium was then replaced 
after 24 hours when cells had been adherent to the flasks' ground. 
2.3.3 Herbs preparations for cell culture 
In this study, only the effects of the aqueous extracts of Epimedium 
and Ligustrum were tested owing to the time limitation. Different 
concentrations of the herbal extracts were prepared by dissolved the 
lyophilized herbal extract powders in medium containing 10% (v/v) heat 
inactivated FBS, penicillin (100U/ml) and streptomycin (100|jg/ml) and 
sonicated for 10 minutes in an ultrasonic disrupter. They were then filtered 
with 0.22|jm-pore-size Millex-GV filter unit (Millipore, Malsheim, France). 
They were prepared freshly just before adding to the cell cultures. 
2.3.4 Cell viability assay 
UMR-106 cells were removed from culture flasks by trypsinization and 
200pl aliquots of cell suspension were seeded in the wells of 96-well plate at 
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5x10^ cells/well in DMEM containing 10% (v/v) heat inactivated FBS, 
penicillin (100U/ml) and streptomycin (100|jg/ml). After 24 hours, the medium 
was replaced with fresh medium containing different concentrations (0， 
0.0625，0.125 and 0.25mg/ml) of the aqueous extracts of Epimedium or 
Ligustrum and incubated for 24 hours. 
Relative cell viability was determined by the 3-[4,5 dimethylthiazol 2-yl]-
2,5-diphenyltetrazolium bromide (MTT) assay (Carmichael et al., 1987) with 
modification. SOpI of 5mg/ml MTT in PBS was added to the medium. The 
wells without cells were used as blanks. The cells were incubated for 4 hours 
in a humidified 5% CO2 atmosphere at 37�C. It was followed by removal of 
medium and addition of 100|jl DMSO. The plate was shaken gently on an 
orbital shaker for 10 minutes, and the absorbance at 540nm was measured 
in Fluostar Optima Microplate Reader with Fluostar Optima software Version 
1.30-0 (BMG Labtechnologies GmbH, Offenburg, Germany). The relative cell 
viability was expressed as the percentage of untreated controls. 
2.3.5 Cellular alkaline phosphatase activity assay 
UMR-106 cells were removed from culture flasks by trypsinization and 
500|jl aliquots of cell suspension were seeded in the wells of 24-well plates 
at 6 X 104 cells/well in DMEM containing 10% (v/v) heat inactivated FBS, 
penicillin (100U/ml) and streptomycin (100|jg/ml). After 24 hours, the medium 
was replaced with fresh medium containing different concentrations (0， 
0.0625, 0.125 and 0.25mg/ml) of the aqueous extracts of Epimedium or 
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Ligustrum and incubated for 24 hours and 3 days. Fresh medium and 
aqueous herbal extracts were replenished every 2 days. 
In this assay, medium was removed, and cells were rinsed twice with 
PBS, and extracted into 200|JI lysis buffer consisting of SOmM Tris-HCI, pH 
7.2, with 0.1% (v/v) Triton X-100 and 2mM MgCb. They were then subjected 
to freeze-thaw cycle at -70�C for three times, and sonicated in an ice bath for 
30 seconds using an ultrasonic disrupter. Lysates were pelleted by 
centrifugation at lOOOOxg for 10 minutes and discarded. Supernatants were 
transferred to fresh eppendrofs for assessing alkaline phosphatase (ALP) 
activity. 
ALP activity was determined colorimetrically using the Alkaline 
Phosphatase Kit by a method modified from that of Lowry et al” 1954. ALP 
reagent, which contained substrate, p-nitrophenyl phosphate, was warmed to 
30�C. 30hI aljquots of samples and 170|jl ALP reagent were added to the 
wells of 96-well plate, which had been prewarmed to 30°C. The plate was 
immediately shaken for 30 seconds at 30°C in Fluostar Optima Microplate 
Reader with Fluostar Optima software Version 1.30-0. The absorbance at 
405nm was measured. The plate was kept at 30�C in microplate reader and 
absorbance was recorded at 2-minute intervals for 10 minutes. Before each 
reading, plate was shaken for 30 seconds. The changes in absorbance 
values of samples, which were calculated by subtracting absorbance values 
within the linear range of the reaction from different time points, were 
compared with those of standards (Multi-Enzyme LIN-TROL) with known ALP 
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activities. The ALP activity calculated was expressed as units per milliliter of 
sample. 
In parallel, the protein content of cells in each well was determined by 
modified Bradford Assay (Bradford, 1976). Samples were diluted 5-fold. 40|JI 
aliquots of the diluted samples were added to 160|jl Bio-Rad Protein Assay 
Dye Reagent Concentrate. Different concentrations of bovine serum albumin 
served as standards. The reaction mixtures were incubated at room 
temperature for 10 minutes and absorbance at 595nm was measured. ALP 
activity was normalized with the protein content of cells and expressed as 
units per milligram of protein. 
2.3.6 Matrix mineralization assay 
UMR-106 cells were removed from culture flasks by trypsinization and 
2ml aliquots of cell suspension were seeded in the wells of 6-well plates at 
3.2 X 104 cells/well in DMEM containing 10% (v/v) heat inactivated FBS, 
penicillin (100U/ml) and streptomycin (100|jg/ml). After 24 hours, the medium 
was replaced with fresh medium containing different concentrations (0， 
0.0625 and 0.125mg/ml) of the aqueous extracts of Epimedium or Ligustrum 
and incubated for 6 days and 8 days. Fresh medium and herbal extracts 
were replenished every 2-3 days. 
The degree of mineralization was determined in the 6-well plate using 
Alizarin red S staining as described previously (Reinholz et al., 2000). Briefly, 
the cells were rinsed twice with PBS. The cells were fixed with ice-cold 70% 
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(v/v) ethanol for 1 hour. Ethanol was removed, and the cells were rinsed 
twice with distilled water. The cells were then stained with 40mM Alizarin red 
S, pH 4.2 for 10 minutes. The Alizarin Red S solution was removed, and the 
cells were rinsed five times with distilled water. The plates were then shaken 
gently in PBS on an orbital shaker for 15 minutes. Then PBS was removed, 
and the cells were rinsed once with PBS. The cells were then destained for 
15 minutes with 1ml of 10% (w/v) cetylpyridinium chloride in 10mM sodium 
phosphate, pH 7.0 with gently shaking on an orbital shaker. 200|jl aliquots of 
the extracted stains were then transferred to a 96-well plate, and the 
absorbance at 562nm was measured using Fluostar Optima Microplate 
Reader with Fluostar Optima software Version 1.30-0. The concentrations of 
Alizarin red S in the samples were determined by comparing the absorbance 
values with those of Alizarin red S standards. The mineralization values were 
normalized to the relative cell viability as determined in the 96-well plate by 
MTT assay. 
For MTT assay, UMR-106 cells were removed from culture flasks by 
trypsinization and 200|jl aliquots of cell suspension were seeded in the wells 
of 96-well plates at 2x10^ cells/well in DMEM containing 10% (v/v) heat 
inactivated FBS, penicillin (100U/ml) and streptomycin (100|jg/ml). After 24 
hours, the medium was replaced with fresh medium containing different 
concentrations (0, 0.0625 and 0.125) of the aqueous extracts of Epimedium 
or Ligustrum and incubated for 6 days and 8 days. Fresh medium and herbal 
extracts were replenished every 2-3 days. 
55 
Chapter 2. Materials and methods 
Cell viability was determined by MTT assay as described in Section 
2.3.4. The relative cell viability was expressed as the percentage of untreated 
controls. 
2.3.7 Competitive estrogen receptor binding assay 
MCF-7 cells were removed from culture flasks by trypsinization and 
500|jl aliquots of cell suspension were seeded in the wells of 24-well plate at 
1 X 10® cells/well in RPMI 1640 containing 10% (v/v) heat inactivated FBS, 
penicillin (100U/ml) and streptomycin (lOOpg/ml). After 24 hours, the medium 
was replaced with phenol red-free RPMI containing 10% (v/v) 
charcoal/dextran treated FBS, 1% penicillin-streptomycin for 2 days. 
Competitive estrogen receptor binding assay was performed by a 
method modified from Olea-Serrano et al., 1985. To perform the assay, the 
medium was replaced by serum-free medium containing 2.82nM radiolabeled 
[2’4，6,7-3H(N)�estradiol ([3H�estradiol; 71Ci/mmol) in the presence of different 
concentrations of either non-radiolabeled 17p-estradiol (0，0.05, 0.5, 5，50， 
500 and SOOOnM), which served as positive controls, or aqueous extracts of 
Epimedium or Ligustrum (0，0.0625, 0.125, 0.25，0.5, 1mg/ml), which were 
the tested samples. The plates were incubated for 90 minutes in a humidified 
5% CO2 atmosphere at 37�C. After that, radioactive-labeled cells were 
washed three times with ice-cold PBS. The incorporated [^H]estradiol 
retained in cells was extracted by incubating in 1ml absolute ethanol at room 
temperature for 45 minutes. Then the entire amount of ethanol was 
transferred to mini scintillation vials containing 2 ml of scintillation liquid for 
radioactivity counting in liquid scintillation counter (Beckman Instruments, 
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Fullerton, CA). The amount of receptor-bound [3H]estradiol was calculated 
after correcting for nonspecific binding values obtained from the wells 
containing 2.82nM pH]estradiol plus 5000nM 17p-estradiol. Estrogen 
receptor activity was reported as the percentage of receptor-bound 
[^H]estradiol. 
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2.4 Statistical analyses 
The program used in statistical analysis was GraphPad Prism 
software Version 4.01 (GraphPad Software, San Diego, CA). Data were 
analyzed by one-way ANOVA followed by Tukey's Multiple Comparison Test, 
with p<0.05 considered significant. Numerical values are expressed as the 
mean 土 SEM. The median effective concentration (EC50) values were 
calculated from sigmoid curves fitted to the cumulative concentration-
response data by nonlinear regression using the following formula: 
y = A + (B-A)/[1 + (10^/10^)'^ 
where A is bottom plateau, B is top plateau, C is log(EC5o) and D is slope 
coefficient. 
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Chapter 3. Results 
3.1 Extraction yields of Kidney-tonifying herbs and herbal 
formula 
The extraction yields of Kidney-tonifying herbs and herbal formula 
were shown in Table 3-1. For the animal study, aqueous and ethanol extracts 
of ELP, Epimedium and Ligustrum were prepared. Only the aqueous extracts 
of Epimedium and Ligustrum prepared were also for the cell culture study. 
The yields of the aqueous extracts of ELP, Epimedium and Ligustrum were 
19.7%, 17.1% and 20.6% (w/w)，while those of the ethanol extracts were 
20.0%, 17.9% and 21.0% (w/w) respectively. 
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Table 3-1. The Extraction Yields of Kidney-tonifying Herbs and Herbal 
Formula 
Herb/ Herbal ^ “ Dry Weight of Dry Weight of Yield 
Formula boivent Raw Material (kg) Extract (kg) (%) 
For the cell culture & animal study 
Epimedium H2O 4.80 0.820 17.1 
Ligustrum H2O 5.00 1.030 20.6 
For the animal study 
ELP H2O 6.00 1.180 19.7 
Epimedium 70% Ethanol 5.00 0.896 17.9 
Ligustrum 70% Ethanol 4.00 0.840 21.0 
ELP 70% Ethanol 6.00 1.200 20.0 
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3.2 Effects of Kidney-tonifying herbs and herbal formula 
on the gene expressions of calcium absorption and 
reabsorption related genes 
As mentioned in Section 1.1.3.1.3, calcium absorption from the 
intestine and calcium reabsorption from the kidney is important for skeletal 
health. Although the exact mechanisms of these two processes remain to be 
elucidated, it has been convincingly documented that 1,25-dihydroxyvitamin 
Ds (1，25(0H)2D3)’ which is synthesized and tightly regulated by 25-
hydroxyvitamin D3-Ialpha-hydroxylase (1a-0Hase) in the kidney, facilitates 
calcium absorption and reabsorption by binding to vitamin D receptor (VDR) 
and stimulating the gene expressions of intracellular calcium transporters. 
Among them, it is general accepted that calbindin plays a vital role in vitamin 
D-induced calcium absorption and reabsorption. 
In the animal study, aqueous and ethanol extracts of Kidney-
tonifying herbs, Epimedium and Ligustrum, and the herbal formula, ELP, 
were examined for their influences in calcium absorption in the duodenum 
and calcium reabsorption in the kidney through studying the gene 
expressions of VDR and calbindin D9K (CaBP-D9K) in the duodenum, and 
1a-0Hase, VDR and calbindin D28K (CaBP-D28K) in the kidney of 
ovariectomized (OVX) adult rats by real-time PGR. A group of OVX rats was 
fed with raloxifene, which is a selective estrogen receptor modulator (SERM; 
a class of modern medicine widely used in the treatment of postmenopausal 
osteoporosis). This group served as a reference for comparison. 
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3.2.1 Gene expression of 25-hydroxyvitamin D3-I alpha-
hydroxylase in the kidney 
Effects of the Kidney-tonifying herbs and herbal formula on the gene 
expressions of 1a-0Hase in the kidney were expressed in the relative fold 
inductions in the treatment groups compared with the ovariectomized control 
group, as shown in Figure 3-1. The relative 1a-0Hase gene expression 
levels in the sham and ovariectomized control groups were 2.3 土 0.4 and 1.0 
土 0.3 respectively. This showed that the gene expression level of 1a-0Hase 
was downregulated 2.3-fold by ovariectomy, despite lack of statistical 
significance. 
For the treatment groups, the renal 1a-0Hase expression levels were 
1.1 ± 0 . 3 and 0.9 士 0.2 for the aqueous and ethanol extracts of Epimedium 
respectively; 1.4 土 0.4 and 2.3 土 0.5 for those of Ligustrum', and 1.0 士 0.1 and 
10.6 ± 1.1 for those of ELP. For the raloxifene group, it was 7.8 土 1.0. The 
results showed that the administrations of the ethanol extract of ELP (ELP-
EtOH) and raloxifene upregulated the renal duodenal CaBP-D9K expression 
robustly and significantly by 10.6 and 7.8 fold respectively (P<0.001). 
Although all other treatments did not alter the expression level statistically 
significantly, the ethanol extract of Ligustrum (Lig-EtOH) increased the 1a-
OHase expression level remarkably by 2.32 fold. Since 1a-0Hase is the key 
enzyme involved in the conversion of vitamin D to its hormonally active form 
1，25(0H)2D3, the increase of renal 1a-0Hase expression by ELP-EtOH and 
raloxifene indicated that they might play a role in the regulation of vitamin D 
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metabolism, which could contribute to their bone protective effects (Section 
4.1). 
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Figure 3-1. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Gene Expression of 1a-OHase in the Kidney. Ovariectomized and sham-
operated adult rats received indicated treatments for 21 weeks. After that, 
rats were scarified and the left kidneys were removed. Total RNA was 
isolated, cDNA was prepared and real time PGR was preformed to study the 
differential gene expression of 1a-0Hase in the kidney, as described in 
“Materials and methods" (Section 2.2.5). Fold induction was calculated as the 
normalized ratio of expressions in treatment groups versus control. Each 
point represented the mean 土 SEM of 7-10 determinations. Data were 
analyzed by one-way ANOVA. ***，P<0.001 compared with control. The 
result showed that the ethanol extract of ELP (ELP-EtOH) and raloxifene 
significantly elevated the renal gene expression of 1a-0Hase. 
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3.2.2 Gene expression of vitamin D receptor in the duodenum 
Effects of the Kidney-tonifying herbs and herbal formula on the gene 
expressions of VDR in the duodenum were expressed in the relative fold 
inductions in the treatment groups compared with the ovariectomized control 
group, as shown in Figure 3-2. The relative VDR gene expression levels in 
the sham and ovariectomized control groups were 1.2 土 0.2 and 1.0 土 0.2 
respectively and they were not significantly different from each other. This 
revealed that ovariectomy had no effect on the gene expression of VDR. 
In the treatment groups, the duodenal VDR expression levels were 
1.0 土 0.1 and 1.1 ±0.1 for the aqueous and ethanol extracts of Epimedium 
respectively; 1.2 ± 0.1 and 2.0 土 0.2 for those of Ligustrum] and 1.0 ± 0.1 and 
1.1 土 0.2 for those of ELP. For the raloxifene group, it was 2.1 土 0.3. As 
shown in Figure 3-2, the administrations of the ethanol extract of Ligustrum 
(Lig-EtOH) and raloxifene statistically significantly upregulated the renal VDR 
expressions by 2.0 and 2.1 fold respectively (P<0.01), whereas other 
treatments did not cause significant change. Since the beneficial effects of 
vitamin D on calcium absorption is mediated through its receptor VDR in the 
duodenum, the increase of the duodenal VDR expression by Lig-EtOH and 
raloxifene suggested that the involvements in vitamin D-dependent calcium 
absorption might be one of the contributing factors that these treatments 
exerted beneficial effects to bone health (Section 4.2). 
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Figure 3-2. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Gene Expression of VDR in the Duodenum. Ovariectomized and sham-
operated adult rats received indicated treatments for 21 weeks. After that, 
rats were scarified and duodenum segments were removed. Total RNA was 
isolated, cDNA was prepared and real time PGR was preformed to study the 
differential gene expression of VDR in the duodenum, as described in 
“Materials and methods" (Section 2.2.5). Fold induction was calculated as the 
normalized ratio of expressions in treatment groups versus control. Each 
point represented the mean 士 SEM of 7-10 determinations. Data were 
analyzed by one-way ANOVA. **, P<0.01 compared with control. The result 
showed that the aqueous extract of Ligustrum (Lig-H20) and raloxifene 
significantly increased the duodenal gene expression of VDR. 
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3.2.3 Gene expression of calbindin D9K in the duodenum 
Effects of the Kidney-tonifying herbs and herbal formula on the gene 
expressions of CaBP-D9K in the kidney were expressed in the relative fold 
inductions in the treatment groups compared with the ovariectomized control 
group, as shown in Figure 3-3. The relative CaBP-D9K gene expression 
levels in the sham and ovariectomized control groups were 1.3 土 0.2 and 1.0 
± 0.1 respectively, which was not significantly different. This showed that 
ovariectomy might not affect the gene expression level of CaBP-D9K. 
For the treatment groups, the duodenal CaBP-D9K expression levels 
were 0.7 ± 0 . 1 and 0.5 ± 0 . 1 for the aqueous and ethanol extracts of 
Epimedium respectively; 0.7 ± 0.1 and 0.8 土 0.1 for those of Ligustrum] and 
0.6 士 0.1 and 0.8 士 0.1 for those of ELP. For the raloxifene group, it was 0.8 土 
0.1. None of the treatments altered the expression level significantly. 
However, some of them appeared to reduce the expression level of CaBP-
D9K, especially the ethanol extract of Epimedium (Epi-H20) and aqueous 
extract of ELP (ELP-H20), which downregulated the duodenal CaBP-D9K 
expressions by 2.0 fold, despite not statistically significant. This revealed that 
the preservations of BMD by these treatments, as shown in Figure 4-3， 
seemed not to be related to the gene expression of duodenal CaBP-D9K. 
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Figure 3-3. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Gene Expression of CaBP-D9K in the Duodenum. Ovariectomized and 
sham-operated adult rats received indicated treatments for 21 weeks. After 
that, rats were scarified and duodenum segments were removed. Total RNA 
was isolated, cDNA was prepared and real time PGR was preformed to study 
the differential gene expression of CaBP-D9K in the duodenum, as described 
in "Materials and methods” (Section 2.2.5). Fold induction was calculated as 
the normalized ratio of expressions in treatment groups versus control. Each 
point represented the mean 土 SEM of 7-10 determinations. Data were 
analyzed by one-way ANOVA. The results showed that there was no 
significant difference in the duodenal gene expression of CaBP-D9K among 
all groups. 
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3.2.4 Gene expression of vitamin D receptor in the kidney 
Effects of the Kidney-tonifying herbs and herbal formula on the gene 
expressions of VDR in the kidney were expressed in the relative fold 
inductions in the treatment groups compared with the ovariectomized control 
group, as shown in Figure 3-4. The relative VDR gene expression levels in 
the sham and ovariectomized control groups were 1.4 土 0.2 and 1.0 ± 0.1 
respectively. As they were not significantly different from each other, 
ovariectomy might not affect on the gene expression of VDR. 
For the treatment groups, the renal VDR expression levels were 1.6 土 
0.2 and 1.0 土 0.1 for the aqueous and ethanol extracts of Epimedium 
respectively; 1.2 ± 0.1 and 0.9 士 0.1 for those of Ligustrum; and 1.2 ± 0.1 and 
0.9 土 0.1 for those of ELP. For the raloxifene group, it was 0.9 土 0.1. Among 
them, only the administration of the aqueous extract of Epimedium (Epi-H20) 
statistically significantly upregulated the renal VDR expression by 1.6 fold 
(P<0.01), whereas other treatments had no significant effect on the 
expression level. Despite that, the aqueous extract of Ligustrum (Lig-H20) 
and ELP (ELP-H20) also appeared to positively modulate, although not 
statistically significantly, the RNA levels of renal VDR by 1.2 fold. The results 
offered a clue that the aqueous extracts of Kidney-tonifying herbs and herbal 
formula used in the present study, particularly Epimedium, might be involved 
in vitamin D-dependent calcium reabsorption, which might partially account 
for the favourable effects of these treatments on bone (Section 4.2). 
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Figure 3-4. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Gene Expression of VDR in the Kidney. Ovariectomized and sham-
operated adult rats received indicated treatments for 21 weeks. After that, 
rats were scarified and the left kidneys were removed. Total RNA was 
isolated, cDNA was prepared and real time PGR was preformed to study the 
differential gene expression of VDR in the kidney, as described in "Materials 
and methods" (Section 2.2.5). Fold induction was calculated as the 
normalized ratio of expressions in treatment groups versus control. Each 
point represented the mean 土 SEM of 7-10 determinations. Data were 
analyzed by one-way ANOVA. **, P<0.01 compared with control. The results 
showed that the aqueous extract of Epimedium significantly elevated the 
renal gene expression of VDR. 70 
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3.2.5 Gene expression of calbindin D28K in the kidney 
Effects of the Kidney-tonifying herbs and herbal formula on the gene 
expressions of VDR in the kidney were expressed in the relative fold 
inductions in the treatment groups compared with the ovariectomized control 
group, as shown in Figure 3-5. The relative CaBP-D28K gene expression 
levels in the sham and ovariectomized control groups were 1.8 土 0.4 and 1.0 
土 0.1 respectively. This revealed that ovariectomy might slightly 
downregulated the gene expression level of CaBP-D28K by 1.8 fold. 
However, they were not statistically significantly different. 
For the treatment groups, the renal CaBP-D28K expression levels 
were 2.0 土 0.2 and 1.3 土 0.2 for the aqueous and ethanol extracts of 
Epimedium respectively; 1.8 土 0.3 and 2.3 土 0.4 for those of Ligustrum; and 
3.2 土 0.5 and 1.4 土 0.3 for those of ELP. For the raloxifene group, it was 1.7 土 
0.3. As revealed in Figure 3-5, the administration of the aqueous extract of 
ELP (ELP-H20) statistically significantly upregulated the renal CaBP-D28K 
expression by 3.2 fold (P<0.001), whereas other treatments had no 
significant effect on the expression level. Despite that, all other treatments 
groups also seemed to slightly elevate renal CaBP-D28K expression levels. 
Thus, the figures implied that ELP-H20 increased gene expression of vitamin 
D-dependent CaBP-D28K, which is involved in calcium reabsorption. Thus, 
ELP-H20 might have stimulatory effect on the calcium conservation from the 
kidney and preserved BMD. 
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Figure 3-5. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Gene Expression of CaBP-D28K in the Kidney. Ovariectomized and 
sham-operated adult rats received indicated treatments for 21 weeks. After 
that, rats were scarified and the left kidneys were removed. Total RNA was 
isolated, cDNA was prepared and real time PGR was preformed to study the 
differential gene expression of CaBP-D28K in the kidney, as described in 
“Materials and methods" (Section 2.2.5). Fold induction was calculated as the 
normalized ratio of expressions in treatment groups versus control. Each 
point represented the mean 土 SEM of 7-10 determinations. Data were 
analyzed by one-way ANOVA. ***, P<0.001 compared with control. The 
results showed that the aqueous extract of ELP (ELP-H20) significantly 
increased the renal gene expression of CaBP-D28K. 
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3.3 Effects of Kidney-tonifying herbs on osteoblastic 
UMR-106 cell line 
The accelerated bone remodeling rate with bone resorption exceeding 
bone formation triggered by estrogen deficiency is the main cause of 
postmenopausal osteoporosis. Induction of bone formation could be 
advantageous in reducing bone loss. As the bone formation ability is 
influenced by the number and activities of osteoblast in the resorption pit, it is 
obvious that stimulating osteoblast proliferation and differentiation may be 
conducive to the counteraction of bone loss in postmenopausal women. 
3.3.1 Effects of Kidney-tonifying herbs on the cell viability of 
UMR-106 cells 
MTT assay was used to measure the relative cell viability. When UMR-
106 cells were treated with 0 (untreated control), 0.0625mg/ml and 
0.25mg/ml of the aqueous extracts of Epimedium and Ligustrum for 24 hours, 
the relative cell viability did not change statistically significantly compared 
with the untreated control, in which cells were incubated with medium only 
(Figure 3-6). The survival rates，when cells were treated with 0.0625mg/ml, 
0.125mg/ml and 0.25mg/ml of the aqueous extracts of Epimedium, were 93.4 
土 2.20/0, 109.8 ± 3.5% and 110.1 土 2.7o/o，whilst those of Ligustrum were 
100.3 ± 4.1%，98.4 土 3.9o/o and 99.1 土 3.7% respectively. The survival rate of 
the untreated control was 100.0 土 1.6�/o. This showed that the doses of the 
aqueous extracts of Epimedium and Ligustrum below 0.25mg/ml were 
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nontoxic to UMR-106 cells. What's more, for O.IZSmg/ml and 0.25mg/ml of 
the aqueous extracts of Epimedium, the relative cell viabilities were 
statistically significantly higher than the untreated control (P<0.05)，which 
suggested that the aqueous extracts of Epimedium might slightly stimulate 
osteoblast proliferation. 
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Figure 3-6. Effects of Kidney-Tonifying Herbs on the Cell Viability of 
UMR-106 Cells. UMR-106 cells were exposed to different concentrations (0， 
0.0625, 0.0125, 0.25mg/ml) of the aqueous extracts of Epimedium and 
Ligustrum for 24 hours. Cell Viability was assayed by MTT assay as 
described in "Materials and methods" (Section 2.3.4). Each point represented 
the mean 土 SEM of 16 determinations from two independent experiments. 
Data were analyzed by one-way ANOVA. *, P<0.05 compared with the 
untreated control. The results showed that 0.125mg/ml and 0.25mg/ml of the 
aqueous extracts of Epimedium significantly but slightly stimulated osteoblast 
proliferation. 75 
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3.3.2 Effects of Kidney-tonifying herbs on the osteoblastic 
differentiation of UMR-106 cells 
3.3.2.1 Cellular alkaline phosphatase activity 
Alkaline phosphatase (ALP) production is a basic marker of osteoblastic 
maturation and activity. The effects of the aqueous extracts of Kidney-
tonifying herbs, Epimedium and Ligustrum, on the cellular ALP activity of 
UMR-106 cells were shown in Figure 3-7. For 24-hour treatment, the cellular 
ALP activities, when cells were treated with 0 (untreated control), 0.0625， 
0.125, and 0.25mg/ml of the aqueous extracts of Epimedium, were 0.499 土 
0.046, 0.505 土 0-074, 0.416 ±0.136 and 0.288 士 0.050U/mg protein, whilst 
those of Ligustrum were 0.578 土 0.066，0.473 土 0.074，0.387 土 0.049 and 
0.325 士 0.020U/mg protein respectively. The cellular ALP activity did not 
change statistically significantly, except at 0.25mg/ml of the aqueous extract 
of Ligustrum, which had a significantly lower level of cellular ALP activity, 
when compared with the untreated control in which cells were incubated with 
medium only (P<0.05). 
Treatments with the aqueous extracts of Epimedium and Ligustrum for 
24 hours showed that the cellular ALP activity gradually decreased with 
increasing concentrations of the herbal extracts in dose-dependent manner, 
despite most of the changes were not statistically significant. The mean 
cellular ALP activity decreased by 16.6% and 42.3% when treated 0.125 and 
0.25mg/ml of the aqueous extracts of Epimedium respectively. Meanwhile, 
the mean cellular ALP activity decreased by 18.3%, 33.0% and 42.3% when 
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treated 0.0625，0.125 and 0.25mg/ml of the aqueous extracts of Ligustrum 
respectively. 
Similar to 24-hour treatment, treating with 0.0625mg/ml to 0.25mg/ml of 
the aqueous extracts of Epimedium and Ligustrum for 3 days suppressed the 
cellular ALP activities of UMR-106 ceils. The cellular ALP activity, when cells 
were treated with 0 (untreated control), 0.0625, 0.125, and 0.25mg/ml of the 
aqueous extracts of Epimedium, were 1.541 土 0.153，0.861 土 0.046, 0.930 土 
0.028 and 1.079 土 0.092U/mg protein, whilst those of Ligustrum were 1.466 土 
0.186，1.060 土 0.162，1.046 土 0.162 and 1.308 土 0.122U/mg protein 
respectively. For all concentrations of the aqueous extract of Epimedium 
tested, the cellular ALP activities of UMR-106 cells decreased statistically 
significantly compared with the control (p<0.01 for 0.0625 and 0.125mg/ml of 
the aqueous extracts of Epimedium; p<0.05 for 0.25mg/ml of that of 
Epimedium). For all concentrations of the aqueous extract of Ligustrum 
tested, the cellular ALP activities of UMR-106 ceils decreased when 
compared with the control but the changes were not statistically significant. 
In contrast with 24-hour treatment, the decreases in the cellular ALP 
activities seemed to be reduced when the concentration of the herbal 
extracts in the medium increased after 3-day treatment. The mean cellular 
ALP activity decreased by 44.1%, 39.7% and 30.0% when treated 0.0625, 
0.125 and 0.25mg/ml of the aqueous extracts of Epimedium respectively. 
Meanwhile, the mean cellular ALP activity decreased by 27.7%, 28.6% and 
10.8% when treated 0.0625, 0.125 and 0.25mg/ml ofthe aqueous extracts of 
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Ligustrum respectively, compared with the untreated control in which cells 
were incubated with medium only. 
The results revealed that the aqueous extract of Epimedium might 
slightly suppress ALP activity, whereas the aqueous extract of Ligustrum 
appeared to have a much minor effect. This implies that Epimedium may 
slightly but negatively modulate osteoblastogenesis. 
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Figure 3-7. Effects of Kidney-tonifying Herbs on the Cellular ALP 
Activity of UMR-106 Cells. UMR-106 cells were exposed to different 
concentrations of the aqueous extracts of Epimedium (A) and Ligustrum (B) 
for 24 hours and 3 days. Cellular ALP activity was assayed as described in 
"Materials and methods” (Section 2.3.5). Each point represented the 
mean 土 SEM of 4 determinations from an experiment, which was the 
representative of two independent experiments. Data were analyzed by one-
way ANOVA. *, P<0.05; **, P<0.01 compared with the time-matched 
untreated control. The results showed that 3-day treatment of the aqueous 
extracts of Epimedium slightly but significantly reduced the cellular ALP 
activity whereas those of Ligustrum showed a much minor effect. 
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3.3.2.2 Degree of matrix mineralization 
We also tested the effects of the aqueous extracts of Kidney-tonifying 
herbs on the ability of UMR-106 cells to mineralize the extracellular fluid, 
which examined the direct effects of the aqueous extracts of Epimedium and 
Ligustrum on bone matrix mineralization. UMR-106 cells deposited a calcium-
rich mineralized matrix by Day 6. The measured degrees of mineralization 
were normalized with the survival rate, as shown in Figure 3-8. When treated 
with 0.0625mg/ml and 0.125mg/ml of the aqueous extracts of Epimedium, 
the relative cell viabilities were 103.3 ± 6.2% and 99.6 土 5.1o/o respectively 
relative to the untreated control, in which cells were incubated with medium 
only. For 0.0625mg/ml and 0.125mg/ml of the aqueous extracts of Ligustrum, 
the relative cell viabilities were 97.8 土 6.7o/o and 95.3 士 2.4o/o respectively. For 
the untreated control, it was 100.0 士 4.0o/o. There was no statistically 
significant difference among all treatments, which revealed that the herbal 
extracts were nontoxic to the cells at indicated concentrations of the herbal 
extracts. 
The normalized degrees of mineralization were 110.4 土 5.9o/o and 94.4 土 
5.3% respectively compared with the untreated control when treated with 
0.0625mg/ml and 0.125mg/ml of the aqueous extracts of Epimedium. For 
those of Ligustrum, the normalized degrees of mineralization were 91.3 土 
7.4% and 129.1 土 3.2o/o respectively. For the untreated control, it was 100 ± 
4.2%. The degree of mineralization increased remarkably and statistically 
significantly at 0.125mg/ml of the aqueous extract of Ligustrum by 129% 
(P<0.01), whereas other treatments did not caused significant change. 
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Figure 3-8. Effects of Kidney-tonifying Herbs on the Degree of Matrix 
Mineralization of UMR-106 cells Day 6. UMR-106 cells were exposed to 
different concentrations of the aqueous extracts of Epimedium and Ligustrum 
for 6 days. The degree of matrix mineralization was determined as described 
in "Materials and methods” (Section 2.3.6). For the cell viability (A), each 
point represented the mean ± SEM of 8 determinations from an experiment, 
which was the representative of two independent experiments. For the 
degree of mineralization (B), each point represented the mean 土 SEM of 8 
determinations from the representative of two independent experiments. Data 
were analyzed by one-way ANOVA. **, P<0.01 compared with the untreated 
control. The results showed that 0.125mg/ml of the aqueous extract of 
Ligustrum significantly increased the degree of matrix mineralization. 
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We further treated UMR-106 cells with 0 (untreated control), 
0.0625mg/ml and 0.125mg/ml of the aqueous extracts of Epimedium and 
Ligustrum for 2 days more. The measured degrees of mineralization were 
normalized with the survival rate, as shown in Figure 3-9. After 8-day 
treatment, the relative cell viabilities were 92.2 土 4.0o/o and 89.9 土 5.6o/o 
respectively when treated with 0.0625mg/ml and 0.125mg/ml of the aqueous 
extracts of Epimedium compared with the untreated control. For 0.0625mg/ml 
and 0.125mg/ml of the aqueous extracts of Ligustrum, the relative cell 
viabilities were 89.1 土 2.3o/o and 96.2 士 2.6o/o respectively. For untreated 
control, it was 100.0 ± 3.1 o/o. There was no significant difference among all 
treatments except at 0.0625mg/ml of the aqueous extract of Ligustrum, in 
which the decrease in the relative cell viability was statistically significant 
(p<0.05). 
The normalized degrees of mineralization were 105.6 土 4.4o/o and 117.0 
土 7.0o/o respectively when treated with 0.0625mg/ml and 0.125mg/ml of the 
aqueous extracts of Epimedium compared with the untreated control. For 
those of the aqueous extracts of Ligustrum, the normalized degrees of 
mineralization were 130.5 ± 3.0o/o and 106.8 土 2.5o/o respectively. For the 
untreated control, it was 100 土 2.9o/o. The degree of mineralization increased 
remarkably and statistically significantly at 0.0625mg/ml of the aqueous 
extract of Ligustrum by 30% (P<0.001), whereas the changes were relatively 
small and insignificant with other treatments. 
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Figure 3-9. Effects of Kidney-tonifying Herbs on the Degree of Matrix 
Mineralization of UMR-106 cells Day 8. UMR-106 cells were exposed to 
different concentrations of the aqueous extracts of Epimedium and Ligustrum 
for 8 days. The degree of matrix mineralization was determined as described 
in “Materials and methods” (Section 2.3.6). For the cell viability (A), each 
point represented the mean 土 SEM of 8 determinations from an experiment, 
which was the representative of two independent experiments. For the 
degree of mineralization (B), each point represented the mean 土 SEM of 8 
determinations from the representative of two independent experiments. Data 
were analyzed by one-way ANOVA. *, P<0.05; ***, P<0.001 compared with 
the untreated control. The results showed that 0.0625mg/ml of the aqueous 
extracts of Ligustrum significantly increased the degree of matrix 
mineralization accompanied by a slight but significant reduction in the relative 
cell viability. 
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The results for 6- and 8- day treatments of different concentrations of the 
aqueous extracts of Epimedium and Ligustrum demonstrated that the 
aqueous extracts of Ligustrum might facilitate bone matrix mineralization, 
whereas the aqueous extract of Epimedium probably did not have such effect. 
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3.4 Estrogen receptor binding activities of Kidney-
tonifying herbs 
Estrogen receptor mediates the bone protective effects of estrogen. 
Therapeutic agents, like raloxifene, which modulate estrogen receptor and 
exert estrogen-agonist properties in bone, are effective in treating 
postmenopausal osteoporosis. To determine whether Kidney-tonifying herbs 
are involved in estrogen receptor-mediated mechanism, competitive estrogen 
receptor binding assay was performed. Indicated concentrations of non-
radiolabeled 17p-estradiol (positive control) or aqueous extracts of herbs 
competed with pH]estradiol for the binding sites on estrogen receptors in 
MCF-7 breast cancer cells. The lower the percentage of radioactivity, the 
higher is the competition for estrogen receptor binding. 
Figure 3-10 showed how [^H]estradiol binding was blocked by the 
competition with 17p-estradiol in a dose-dependent manner. Similarly, the 
increases in the concentration of the aqueous extract of Epimedium also 
caused a reduction of [3H]estradjol binding. The median effective 
concentration (EC50) of 17p-estradiol and the aqueous extract of Epimedium 
were 0.142nM and 0.471 mg/ml respectively. This indicated that the aqueous 
extract of Epimedium bound estrogen receptor. In contrast, the percentage of 
radioactivity did not show dose-dependent response to different 
concentrations of the aqueous extract of Ligustrum, which suggested that it 
might not bound estrogen receptor. The results suggested that some of the 
biological actions of the aqueous extract of Epimedium might be mediated 
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through estrogen receptor. However, this possibility was not proved in the 
present studies. 
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Figure 3-10. Estrogen Receptor Binding Activities of Kidney-tonifying 
Herbs. MCF-7 cells were exposed to different concentrations of non-
radiolabeled 17p-estradiol (A), or aqueous extracts of Epimedium or 
Ligustrum (B) in the presence of 2.82nM radiolabeled [^H]estradiol. Estrogen 
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Figure 3-10. (continued) 
receptor binding assay was carried out as described in "Materials and 
methods" (Section 2.3.7). Each point represented the mean 士 SEM of 2-3 
determinations from an experiment, which was the representative of two 
independent experiments. The results showed that non-radiolabeled 17p-
estradiol and the aqueous extract of Epimedium significantly displaced 
[^H]estradiol in this assay, whereas the aqueous extract of Ligustrum was 
inactive. 
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Chapter 4. Discussion 
4.1 Safety of Kidney-tonifying herbs and herbal formula 
In the animal study, body weight and uterine wet weight were recorded to 
monitor the safety of the aqueous and ethanol extracts of the Kidney-
tonifying herbal formula, ELP, and its major ingredients, Epimedium and 
Ligustrum, to rats. The data were kindly provided by my laboratory 
collaborator, Mr. Ye Sun (Personal communication). 
Body weights measured were shown in Figure 4-1. It is expected that 
ovariectomy increases body weight (Geiselman & Almli, 1978). However, the 
expected result was not observed, as there was no significant difference in 
body weight between the sham and ovariectomized control group. It could be 
related to the restricted amount of food given to rats (17g/5 rats/day). 
Administrations of the ethanol extract of ELP (ELP-EtOH) and raloxifene 
reduced body weights and the reductions were statistically significant (12.2% 
and 10.0% respectively) 6 weeks after treatment started when compared with 
the ovariectomized control group. Raloxifene has been shown to lower the 
body weight in previous studies. It was suggested to be associated with the 
reversions of ovariectomy-induced increases in food intake and fat mass 
content (Meli et al., 2004; Sato et al., 1998). The reduction in body weight 
caused by administration of the ethanol extract of ELP is speculated to be 
owing to changes in appetite or fat distribution within the body, or it may be 
slightly toxic to the rats. Other herbal extracts should be safe to administrate. 
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Figure 4-1. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Body Weight of Rats. (A) Body weight measured during the course of 
treatment. (B) Body weight measured at 6 and 18 week after treatment 
started. Each point represented the mean 士 SEM for 7-10 rats/group. Data 
were analyzed by one-way ANOVA. *, P<0.05; **, P<0.01 compared with 
control. The results showed that the body weights of rats receiving the 
ethanol extract of ELP and raloxifene were significantly low compared with 
time-matched control. The data were kindly provided by my laboratory 
collaborator, Mr. Ye Sun (personal communication). 
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Uterine weight is used to measure the uterotrophic effects of drugs or 
chemicals and serves as an index to estimate their relative estrogenicity. As 
shown in Figure 4-2, the uterine wet weights of rats, which were measured at 
the end of the treatment period, in the ovariectomized control group was 
significantly lower that those in the sham group. This revealed that 
ovariectomized rats were, most likely, hypoestrogenic. There was no 
significant difference in uterine wet weight between the ovariectomized 
control group and the herbal extract treatment groups. This indicates that 
these herbal extracts have no estrogenic effect on the uterus. It has been 
well established that prolonged administration of estrogens for the treatment 
of postmenopausal osteoporosis is involved in the development of uterine 
cancer (Paganini-Hill et al., 1989). The lacking of significant estrogenic effect 
on the uterus implies that the potency of these herbal extracts in inducing 
uterine cancer is low, if not absent. In contract, administration of raloxifene 
significantly elevated uterine wet weight by 97.9% compared with control. 
The uterine wet weight was equivalent to 53.3% of sham. Previous published 
data revealed that raloxifene level had no or marginal stimulatory effect on 
uterine proliferation in ovariectomized rats (Ashby et al., 1997; Evans at al., 
1996). Sun's result seems to show a more pronounced effect than those of 
previous studies, which may be partially because of differences in the ages of 
rats, dosage of raloxifene administrated and duration of treatment. Despite 
that, it was significantly lower than that of the sham group. In addition, there 
is no report that raloxifene administration is associated with uterine pathology 
(de Azevedo et al” 2004). In view of these, Sun's result may be clinically 
irrelevant. 
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Figure 4-2. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Uterine Wet Weight of Rats. Uterine wet weight was measured at Week 18 
after treatment started. Each point represented the mean 土 SEM for 7-10 
rats/group. Data were analyzed by one-way ANOVA. *，P<0.05; ***, P<0.001 
compared with control. ***, P<0.001 compared with sham. The results 
showed that the uterine wet weights of rats in all treatment groups and 
control group were significantly lower that those in the sham group and 
raloxifene administration significantly elevated uterine wet weight compared 
with control. The data were kindly provided by my laboratory collaborator, Mr. 
Ye Sun (personal communication). 
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4.2 Kidney-tonifying herbs and herbal formula preserve 
bone mineral density 
Traditional Chinese medicine claims that the Kidney dominates the 
Bones and the Kidney network determines bone health. Based on this theory, 
the present studies were carried out to investigate whether the aqueous and 
ethanol extracts of the Kidney-tonifying herbal formula, ELP, and its major 
ingredients, Epimedium and Ligustrum, exhibit favorable effects on 
postmenopausal osteoporosis. The effect of extracts of Psoralea, which was 
the remaining ingredient of ELP, was not investigated in the present study 
owing to inadequate manpower. 
During the treatment period in the animal study, the spinal bone mineral 
densities (BMD) of rats were measured by dual energy x-ray absorptiometry 
(DEXA) technique. The data were kindly provided by my laboratory 
collaborator, Mr. Ye Sun (Personal communication). 3 weeks after 
ovariectomy, all rats showed significant reduction in spinal BMD, ranged from 
10.1% to 12.0% and they were considered at the state of postmenopausal 
osteoporosis (Figure 4-3). The results of the present study went along with 
the traditional Chinese medicine theory that Kidney-tonifying herbs and 
herbal formula preserved BMD. After 18 weeks of treatment, administrations 
of the aqueous and ethanol extracts of Epimedium, Ligustrum and ELP 
reduced the spinal bone loss by 32.1% to 46.5%, compared with the 
ovariectomized control group, despite the fact that the spinal BMD in these 
groups were still significantly lower than the sham group. The effects of the 
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aqueous extracts of Ligustrum (Lig-H20) and ELP (ELP-H20) and the 
ethanol extract of Ligustrum (Lig-EtOH) are not statistically significantly 
different from raloxifene, which reduced spinal BMD loss by 63.2%. 
Raloxifene, a selective estrogen receptor modulator (SERM), increases 
BMD, decreases biochemical markers of bone turnover, and reduces 
vertebral fracture risks in postmenopausal women (Kanis et al., 2003; 
Weinstein et al., 2003). in Sun's study, the results were in accordance with 
the previous studies on raloxifene in terms of preservation of spinal BMD. 
However, previous studies showed the raloxifene significantly increased 
spinal BMD in postmenopausal women with osteoporosis (Morii et al” 2003), 
whereas, in Sun's study, administration of raloxifene could only prevent 
spinal BMD loss compared with just before treatment started (Week 0). Such 
a difference may be, at least partially, due to the fact that rats were fed with 
restricted calcium (0.1%) diet during the treatment period and thus the 
availability of calcium for bone was limited and the extent of the change in 
BMD was compromised. 
Similar to raloxifene but to a lesser extent, the administrations of 
aqueous and ethanol extracts of Epimedium, Ligustrum and ELP reduced 
BMD loss compared with baseline. These findings suggest that these Kidney-
tonifying herbs and herbal formula could be beneficial to bone health as well 
as potentially effective in treating postmenopausal osteoporosis. To gain a 
better understanding of these observations, further studies were undertaken 
to investigate the actions of Epimedium, Ligustrum and ELP at the cellular 
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and molecular levels. We hypothesized that the aqueous and ethanol 
extracts of the Kidney-tonifying herbal formula, ELP, and its major ingredients, 
Epimedium and Ligustrum may exert their effects via acting on either calcium 
homeostasis, bone metabolism, or both. 
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Figure 4-3. Effects of Kidney-tonifying Herbs and Herbal Formula on the 
Spinal BMD. (A) Spinal BMD measured during the course of treatment. (B) 
Change in Spinal BMD from Week - 3 to Week 18. Each point represented 
the mean 士 SEM for 7-10 rats/group. Data were analyzed by one-way 
ANOVA. **, P<0.01; ***�P<0.001 compared with control. **�P<0.01; 
P<0.001 compared with sham. The results showed that the extracts of 
Kidney-tonifying herbs and herbal formula significantly reduced spinal BMD 
loss compared with the control group. The data were kindly provided by my 
laboratory collaborator, Mr. Ye Sun (personal communicatjon). 
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4.3 Kidney-tonifying herbs and herbal formula modulate 
calcium homeostasis 
Intestinal calcium absorption and renal calcium reabsorption determine 
the availability of calcium in the body and the increase of which could offer 
benefit to BMD. Investigation on the effects of the aqueous and ethanol 
extracts of the Kidney-tonifying herbal formula, ELP, and its major ingredients, 
Epimedium and Ligustrum on calcium homeostasis was carried out. 
4.3.1 Roles in renal synthesis of the hormonally active form of 
vitamin D: 1,25-dihydroxyvitamin D3 
Biological activation of vitamin D consists of two steps: 25-hydroxylation 
of vitamin D in liver followed by lalpha-hydroxylation of 25-hydroxyvitamin D 
(25(0H)D3) in the kidney. The latter hydroxylation is catalyzed by 1a-0Hase 
and the hormonally active form vitamin D, 1，25(OH)2D3 is formed. The 
production of serum 1，25(OH)2D3 level is via tight regulations of renal 1a-
OHase activity as well as the activity of renal 25-hydroxyvitamin D3-24-
hydroxylase (24-OHase), which catalyzes the side chain hydroxylation 
reactions that inactivate 1’25(OH)2D3 (Anderson et al., 2004). 
The real-time PGR data showed that the administrations of the ethanol 
extract of ELP (ELP-EtOH) and raloxifene induced the gene expressions of 
1a-0Hase robustly by 10.6 and 7.8 fold respectively (Figure 3-1). The results 
suggest that administrations of ELP-H20 and raloxifene could positively 
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modulate the production of 1,25(OH)2D3’ as the lalpha-hydroxylation of 
25(0H)D3 to 1，25(0H)2D3 catalyzed by 1a-0Hase is the rate-determining 
step in the production of 1’25(OH)2D3. 1’25(OH)2D3 plays a regulatory role 
with regards to calcium homeostasis, which has been convincingly 
demonstrated in the findings that elevated 1,25(OH)2D3 synthesis are 
observed during low-calcium state, whereas the production of 1，25(OH)2D3 is 
suppressed during high calcium condition, and disorders of the actions of 
1,25(0H)2D3 lead to hypocalcemia, rickets and osteomalacia. However, 
researches on the effect of aging on the adaptations to dietary alterations 
have also demonstrated that the capacity of a low calcium diet and high 
phosphorous diet to induce renal 1a-0Hase expression and subsequently 
produce 1’25(OH)2D3 is decreased in adult rats compared with young rats 
(Armbrecht et al.，1999; Lai et al., 2003). As it has been recently discovered 
that downregulation of 1a-0Hase gene expression is potentially contributed 
to the pathogenesis of inflammation-associated osteopenia/osteoporosis 
(Ebert et al., 2004)，the age-related reduction in the expression of 1a-0Hase 
could contribute to the involvement of vitamin D insufficiency in the 
pathogenesis of postmenopausal osteoporosis. Based on these findings, it 
can be deduced that elevated expressions of 1a-0Hase by ELP-EtOH and 
raloxifene probably exert favorable effects on postmenopausal osteoporosis. 
It is worth noting that the renal 1a-0Hase gene expression induced by 
ELP-EtOH is much larger that those of its two major ingredients, Epimedium 
(Epi-EtOH) and Ligustrum (Lig-EtOH). It may be contributed by the effect of 
Psoralea in ELP-EtOH. However, it may also be possible that there is 
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synergetic effect of the three ingredients (Epimedium, Ligustrum and 
Psora/ea) of ELP-EtOH on the gene expression of renal 1a-OHase. It is a 
pity that the effect of the ethanol extract of Psoralea was not examined and 
the likelihood of the above possibility could not be determined in the present 
studies. 
4.3.2 Roles in calcium absorption in the duodenum 
Calcium absorption in gastrointestinal tract is regulated large extent by 
1,25(OH)2D3, mediated through its nuclear receptor VDR. Vitamin D-
mediated transcellular calcium absorption largely localized in the duodenum, 
because the vitamin D-dependent calcium transport protein, CaBP-D9K, 
which is actively involved in calcium absorption, is only specifically active in 
the enterocytes - the major epithelial cells of the duodenal mucosa (Waiters 
et al., 1999), and its expression level gradually decreases distally. Thus, the 
duodenum was chosen as the target site for the investigation of calcium 
absorption in the gastrointestinal tract in the present study. 
The real-time PCR data showed that the administrations of the ethanol 
extract of Ligustrum (Lig-EtOH) and raloxifene significantly upregulated the 
gene expression of VDR in the duodenum of ovariectomized adult rats by 2.0 
and 2.1 fold respectively (Figure 3-2). VDR level is an important determinant 
of the intestinal responsiveness to 1,25(OH)2D3. A recent study of genetically 
mutant mice demonstrated that endogenous elevated 1,25(OHhD3 could not 
normalize the reduced serum calcium level in VDR-1- mice, while exogenous 
1 ,25(OH)2D3 could normalize calcium in the 1 a-OHase-l- mice, which retained 
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an intact VDR (Panda et al., 2004). The findings confirmed the importance of 
the VDR and 1 ’25(OH)2D3 in intestinal calcium absorption, which has been 
generally accepted. Furthermore, available data also proposed that, given 
normal level of circulating 1,25(OH)2D3, increased intestinal VDR could result 
in increased functional VDFM’25(OH)2D3 complexes, which exerted 
biological actions in enterocytes to increase intestinal calcium transport (Li et 
a/., 1993). Consistent with this, study using human enterocyte cell line stably 
transfected with VDR showed that increased enterocyte VDR level enhanced 
1，25(OH)2D3-mediated calcium transport (Shao et al., 2001). On the basis of 
these findings, upregulation of duodenal VDR gene expression in the present 
study indicates a possible, most likely stimulatory, role on calcium absorption 
of Lig-EtOH and raloxifene. 
Nonetheless, all treatments did not significantly change the gene 
expression level of duodenal CaBP-D9K, which is one of the best 
documented biological markers of the hormonal action of 1，25-(OH)2D3 at the 
genomic level (Liel ef al., 1999)，as shown in Figure 3-3. The results imply 
that, despite modulation of VDR gene expression, administrations of Lig-
EtOH and raloxifene cannot alter the response of the marker of VDR activity 
in the duodenal mucosa to 1’25(OH)2D3. There is no conclusive explanation 
for this observation. However, it has already been previously reported the 
altered interplay between 1 ’25(OH)2D3 and intestinal CaBP-D9K expressions 
in some special circumstances. For instance, hypercalcemia suppressed 
CaBP-D9K expression but caused no change in the plasma concentration of 
1’25(0H)2D3， and, on the other hand, reduced plasma calcium 
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concentrations modulated the stimulatory effect of 1,25(OH)2D3 on the 
duodenal CabP-D9K synthesis (Hemmingsen et a/.，2002). Thus, the 
unresponsiveness of CaBP-D9K gene expression to the altered VDR gene 
expression level may be in part associated with the compromised 
extracellular calcium balance resulted in the restricted calcium diet with 
calcium content of 0.1 g per 100g, the rats received in the present study. In 
addition, the advanced ages of the rats, which were 11-months old at the 
start and 15-months old at the end of the treatment period, appear to 
influence the strength of interactions between 1,25(OH)2D3 and CaBP-D9K. 
A study on aged rats has suggested a dual defect in vitamin D metabolism in 
old animals: one defect related to the low circulating level of 1，25(OH)2D3 and 
a second defect related to a relative intestinal resistance to the action of 
1,25(0H)2D3, which is apparently not due to a reduction in intestinal VDR 
levels (Wood et al” 1998). Other group demonstrated that the capacity of a 
low calcium diet to significantly increased CaBP-D9K protein levels declined 
markedly with age in the duodenum of rats, where the decreased CaBP-D9K 
protein levels were directly attributable to decreased mRNA levels 
(Armbrecht et al., 2003). These findings suggest that decreased circulating 
level of 1，25(0H)2D3 as well as reduced CaBP-D9K gene expression, even 
upon stimulation by decreased calcium level, on aged rats may be partially 
responsible to the present observations. 
Although Lig-EtOH and raloxifene, which upregulated the gene 
expression of VDR in the duodenum, showed no effect on the gene 
expressions of duodenal CaBP-D9K, their potential beneficial effects on 
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calcium absorption should not be negated. There are evidences showing 
that 1，25(0H)2D3 could stimulate factors other that CaBP-D9K, which are 
also involved in the induction of vitamin D-dependent calcium transport 
across the intestine, like the epithelial calcium channel TRPV5 and TRPV6 
(Bouillon et al” 2003). It is speculated that Lig-EtOH and raloxifene interact 
with these factors and exert their effects. However, this probability cannot be 
ruled out in the present study. 
4.3.3 Roles in calcium reabsorption in the kidney 
Similar to the duodenum, vitamin D-dependent calcium transport also 
plays a crucial role in the renal reabsorption of calcium, an important 
mechanism in the regulation of serum calcium, by exerting its effects via 
binding to VDR. Vitamin D-dependent CaBP-D28K, which is exclusively 
localized in the distal convoluted tubule and in the proximal part of the 
collecting ducts, is involved in the regulation of calcium reabsorption in the 
distal convoluted tubule where the majority of filtered calcium is reabsorbed. 
The real-time PGR data showed that the administrations of the aqueous 
extracts of Epimedium (Epi-H20) significantly increased the VDR mRNA 
level by 3.2 fold (Figure 3-4). As previously mentioned, the expression of 
renal VDR is required for 1，25(OH)2D3-mediated renal reabsorption of 
calcium. Besides, it also influences the metabolism of 1’25(OH)2D3. 
Numerous studies have shown that mediated through VDR, 1’25(OH)2D3 
suppresses 1a-0Hase on one hand, and induces 24-OHase on the other 
hand, which, as a feedback mechanism, reduces its own production. In the 
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present study, although Epi-H20 elevated the gene expression of renal VDR, 
it did not significantly change the RNA level of 1a-0Hase, as shown Figure 3-
1. This may imply that the metabolism of 1，25(OH)2D3 may not be affected by 
Epi-H20 administration, whereas the increased renal VDR level may 
influence 1,25(OH)2D3-mediated calcium reabsorption. In fact, the 
importance of renal VDR in calcium conservation in the kidney has been 
reported in multiple studies that VDR inactivation results in hypocalcemia and 
impaired renal calcium reabsorption plays a major role in its development (Li 
et al., 2001; Malloy et al； 1999). These findings suggest that the induction of 
the gene expression of renal VDR by Epi-H20 may facilitate the calcium 
conservation in the kidney. 
In parallel with renal VDR, the gene expression level of renal CaBP-
D28K was also measured. CaBP-D28K, unlike CaBP-D9K, seems to be less 
tightly regulated by VDR-mediated action of 1,25(OH)2D3 as described in the 
findings that CaBP-D28K mRNA levels were only moderately reduced or not 
affected by ablation of the VDR, which could be explained by the possibility 
that the basal expression of CaBP-D28k may be constitutive (Li et al., 1998). 
Nevertheless, the gene expression of CaBP-D28K increases in response to 
elevated 1,25(OH)2D3 (Li et al., 1998). In agreement with this, Epi-H20, 
which increased the renal VDR mRNA level by 3.2 fold and thus might 
enhance 1,25(OH)2D3-VDR transcriptional activity，also elevated the gene 
expression level of CaBP-D28K by 2.0 fold in the present study, despite the 
change in CaBP-D28K level was not statistically significant. In fact, the real-
time PGR data showed that only the administrations of the aqueous extract of 
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ELP (ELP-H20) statistically significantly increased the CaBP-D28K mRNA 
level by 3.2 fold (Figure 3-5). CaBP-D28K is important for renal calcium 
reabsorption, which is supported by experimental evidences that the 
pathogenesis of cyclosporine A-induced hypercalciuria involves the down-
regulation of CaBP-D28K with subsequent impaired renal calcium 
reabsorption (Lee et al., 2002). Furthermore, it has been reported that 
ovariectomy in rats diminishes the gene expression of CaBP-D28K, which 
was also shown in the present study, owing to estrogen deficiency (Criddle et 
al., 1997). This could also account for a rise in calcium excretion in 
postmenopausal women. Therefore, the elevation of CaBP-D28K mRNA 
level may indicate that ELP-H20 administration may facilitate renal calcium 
reabsorption, which may involve in the prevention of postmenopausal 
osteoporosis. 
4.3.4 Summary 
The maintenance of calcium homeostasis is determined by the interplay 
of intestinal absorption, renal excretion and bone remodeling. Defects in 
calcium absorption and reabsorption leads to negative shift of calcium 
balance. This could result in hormonal adaptation, which promotes the 
mobilization of calcium from bone by accelerating bone remodeling and 
increasing the risk of osteoporosis. 
In the present study, the aqueous extract of the Kidney-tonifying herbal 
formula, ELP, induced the gene expression of renal 1a-0Hase, which could 
increase the synthesis of 1，25(OH)2D3. The ethanol extract of Ligustrum 
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increased the mRNA level of duodenal VDR, which is important mediator of 
1，25(OH)2D3-induced calcium absorption. The aqueous extracts of 
Epimedium and ELP upregulated the gene expressions of renal VDR and 
CaBP-D28K respectively, which are involved in calcium reabsorption. Taken 
together, these results indicate that these Kidney-tonifying herbs and herbal 
formula could positively modulate both calcium absorption and reabsorption. 
This beneficial role of these herbs and herbal formula in calcium homeostasis 
may account for the preservation of BMD in rats. 
As a bonus in the present study, raloxifene showed stimulatory effect on 
the gene expression of 1a-0Hase and duodenal VDR, which has not been 
reported before. It has been well established that raloxifene is an 
antiresorptive agent that suppresses bone remodeling and positively 
modulates BMD. The results of the present study implicate that raloxifene 
may also increase duodenal calcium absorption, which could be associated 
with its favorable effects on the treatment of osteoporosis. 
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4.4 Kidney-tonifying herbs modulate bone formation 
Osteoblast development and differentiation plays a crucial role in bone 
formation and maintenance of bone health. In agreement of this, suppression 
of osteoblast survival and impairment of osteoblast response to mechanical 
stimuli caused by estrogen deprivation are important contributing factors of 
the development of postmenopausal osteoporosis (Damien et a/.，1998; 
Garcia-Moreno et al., 2004). As the aqueous extracts of Kidney-tonifying 
herbs, Epimedium and Ligustrum preserved BMD in ovariectomized adult 
rats (Figure 4-3), the potential roles of these herbal extracts in modulating 
osteoblastic proliferation and differentiation of osteoblast were examined 
using UMR-106 ceils, which are rat osteoblast-like osteoscarcoma cells. 
These ceils have many characteristics of osteoblastic cells and have been 
widely used by other researchers in the study of bone physiology 
(Disthabanchong et al., 2002; Morales etal.，2004; Samoto etal•，2003). 
4.4.1 Effects on osteoblast proliferation 
The aqueous extract of Epimedium may have mitogenic effect on UMR-
106 cells. As shown in Figure 3-6, both 0.125mg/ml and 0.25mg/ml of the 
aqueous extract of Epimedium caused approximately 10% increase in the 
relative cell viability. This may implicate that the aqueous extract of 
Epimedium could slightly stimulate osteoblastic proliferation. In contrast, no 
significant change was observed with UMR-106 cells were treated with the 
aqueous extract of Ligustrum, which meant that no stimulatory or inhibitory 
effect on osteoblastic proliferation was induced. 
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4.4.2 Effects on osteoblastic differentiation 
The aqueous extract of Epimedium suppressed alkaline phosphatase 
(ALP) activity after 3-day treatment, while the suppressive effect of aqueous 
extract of Ligustrum on ALP activity was only marginal (Figure 3-7). As ALP 
is a marker of osteoblast functioning and its activity is detected at an early 
stage of osteoblast differentiation and continues to increase during osteoblast 
maturation until the mineralization phase (Stein et al., 1990; Weinreb et al., 
1990), the results of the present study may indicate that the aqueous extract 
of Epimedium exerts mild inhibitory effect on osteoblast functioning. However, 
this action may be associated with its mild promotive effect on osteoblastic 
proliferation that it may retain the cells to a less differentiated but more 
proliferative stage compared with the untreated control. 
I 
Although the aqueous extract of Ligustrum was unable to stimulate 
ALP activity, it positively modulated matrix mineralization in the present study 
whereas the aqueous extract of Epimedium appeared to have no effect 
(Figure 3-8). The aqueous extract of Ligustrum increased the degree of 
matrix mineralization by approximately 30% after 6-day treatment with 
0.25mg/ml of the aqueous extract of Ligustrum and 8-day treatment with 
0.125mg/ml of the extract. The decrease in the relative cell viability 
accompanied by increased degree of matrix mineralization when treated 
0.125mg/ml of the aqueous extract of Ligustrum for 8 days might be because 
the transition of proliferation to differentiation was accelerated with this 
treatment. There is no doubt that the degree of matrix mineralization is a 
strong determinant of bone strength. It has been documented that there is an 
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increase in the stiffness and compressive strength of cancellous tissue when 
the degree of bone matrix mineralization is elevated within a physiological 
range without necessary changes of bone matrix volume and bone 
microarchitecture (Follet et al., 2004). Thus, the mild mineralization-
promoting ability of the aqueous extract of Ligustrum may partially account 
for its capacity to reduce bone loss in the animal model. 
4.4.3 Summary 
In the present study, the aqueous extract of Epimedium slightly 
increased osteoblast proliferation, but slightly reduced ALP activity. This may 
imply that its direct beneficial effects, if any, on the osteoblast growth and 
bone formation are limited. In contrast, the aqueous extract of Ligustrum 
demonstrated favourable effects on bone matrix mineralization. Since the 
accelerated bone remodeling with bone resorption prevailing bone formation 
induced by the decline in estrogen levels after menopause put women at high 
risk for declining BMD and osteoporosis, the mild modulation of matrix 
mineralization suggests a potential therapeutic value of the aqueous extract 
of Ligustrum for the treatment of postmenopausal osteoporosis. 
Nevertheless, since the aqueous and ethanol extracts of Epimedium, 
Ligustrum and ELP reduced spinal BMD loss but were unable to increase 
spinal BMD of ovariectomized rats in the animal study as shown in Figure 4-3， 
it is speculated that the effect on BMD may be owing to a reduction in bone 
resorption rather that an increase in bone formation. Another possibility is 
that the restricted calcium (0.1%) diet fed to rats in the animal study could 
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have adverse effects on bone remodeling, which might mask the mild bone 
matrix mineralization stimulating effects of the aqueous extract of Ligustrum 
on bone. Further investigations are needed to examine these possibilities. 
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4.5 Kidney-tonifying herbs interact with estrogen receptor 
The pathogenesis of postmenopausal osteoporosis is closely related to 
estrogen deficiency after menopause. Some effective therapeutic agents 
treat osteoporosis by interacting with estrogen receptor (ER). For instance, 
raloxifene, which is a SERM, reduces bone loss by modulating estrogen 
receptor and demonstrates estrogen agonist effects on bone. It is interesting 
to investigate whether the bone protective effect of the aqueous extract of 
Kidney-tonifying herbs, Epimedium and Ligustrum, mediated through 
estrogen receptor. In the present study, competitive estrogen receptor 
binding assay on intact MCF-7 cells, which are estrogen receptor-positive 
human breast cancer cells, was performed. The results showed that the 
aqueous extract of Epimedium competed with radiolabeled estradiol for 
estrogen receptor and this meant that some compounds in Epimedium could 
bind estrogen receptor, whereas the aqueous extract of Ligustrum did not 
seem to interact with estrogen receptor. The result suggests that Epimedium 
may contain phytoestrogens, which are worthy for further isolation and 
characterization. It is speculated that the estrogen binding activity may be 
associated with the BMD preserving activity of the aqueous extract of 
Epimedium. However, this possibility was not examined in the present study. 
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4.6 Active ingredients of Kidney-tonifying herbs 
The results of the present studies suggest that the some of aqueous and 
ethanol extracts of the Kidney-tonifying herbal formula, ELP, and its major 
ingredients, Epimedium and Ligustrum, exert beneficial effects on bone 
matrix mineralization, as well as calcium absorption and reabsorption. It is 
worthy of a brief review on the active ingredients in Epimedium, Ligustrum 
and Psoralea to gain a better understanding on these herbs. 
In Epimedium species, icariin appears to be the major active ingredient. 
It has been reported to have therapeutic role in erectile dysfunction, which 
may be related to its ability to restore the endothelial nitric oxide synthase 
(eNOS) expression in corpus cavernosum of arteriogenic erectile dysfunction 
rats and inhibit the activity of cGMP-specific phosphodiesterase type 5 
(PDE5) (Tian et al., 2004; Xin et al., 2003). Besides, it may also be involved 
in anticancer mechanism. It was reported that icariin could influence the 
distribution of the cell cycle of highly metastatic human lung cancer cells and 
reduce S phase. It also increased the cAMP/cGMP ratio in these cells as well 
as reduced adhesive ratio of these cells to laminin substrate and their ability 
of invasion or migration (Mao & Wang, 2000). 
in Ligustrum lucidum Ait , oleanolic acid, ursolic acid and secoiridoid 
glucosides are the major active ingredients. Oleanolic acid has antifungal, 
anti-HIV, diuretic and glucose-lowering activities. Ursolic acid has anti-
angiogenic activity. Both of them have anti-inflamatory, anticancer, 
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cardiotonic and antidysrhythmic effects (Kim et al., 2004; Somova et al., 
2004). It was recently discovered that they exerted inhibitory effects on 
cytochrome P450 isoforms using human liver microsomes, which may be, in 
part, related to their pharmacological activities, including anti-inflammatory 
and anticancer activities (Kim et al., 2004). Besides, oleanolic acid also exert 
hepatoprotective effect, it has been suggested that the underlying 
mechanisms involve its ability of inhibition of the expression of cytochrome 
P450 2E1 (CYP2E1) and blockage of the bioactivation of carbon tetrachloride 
(Jeong et a/., 1999). On the other hand, other reported data suggested that 
the hepatoprotective action exerted by oleanolic acid might be mediated by 
the enhancement of hepatic-glutathione regeneration capacity, particularly 
under conditions of carbon tetrachloride-induced oxidative stress (Yim et al., 
2001). For secoiridoid glucosides from Ligustrum, five of them including 
oleoside dimethyl ester, oleuropein, neonuezhenide, lucidumoside B and 
lucidumoside C, exhibit strong antioxidant effects against hemolysis of red 
blood cells induced by free radicals (He et al., 2001). Meanwhile, four of them, 
including oleuropein, lucidumoside C, oleoside dimethylester and ligustroside, 
show antiviral activities (Ma et al” 2001). 
In Psoralea corylifolia L, the reported active ingredients include 
bakuchiol, bakuchicin, isobavachin, isobavachalcone，neobavaiso-flavone, 
psoralen, psoralidin, psoralin, isopsoralen, 4'-methoxy flavone, corylin, and 
angelicin. Bakuchiol have antimutagenic, antimicrobial, antipyretic and anti-
inflammatory activities (Backhouse et al., 2001; Ferrandiz et al., 1996; 
Katsura et al” 2001; Wall et al., 1988). A study on mice reported that 
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bakuchiol decreased cell migration, myeloperoxidase activity and eicosanoid 
levels in the air pouch inflammation induced by zymosan. In addition, it 
inhibited oedema and myeloperoxidase activity in the 12-0-
tetradecanoylphorbol 13-acetate-induced ear oedema and reduced the PGE2 
content and ear oedema in the arachidonic acid-induced response after 
topical administration. Bakuchiol also exerted hepatoprotective effect on 
tacrine-induced cytotoxicity in a human liver-derived cell line (Cho et al., 
2001). Besides, bakuchiol, isobavachin and isobavachalcone have 
antioxidative activities (Haraguchi et al., 2002). It was demonstrated that they 
inhibited NADPH-, ascorbate-, tertiary butyl hydroperoxide- and carbon 
tetrachloride-induced lipid peroxidation in microsomes, as well as prevented 
NADH-dependent and ascorbate-induced mitochondrial lipid peroxidation. 
Meanwhile, isobavachalcone and neobavaiso-fiavone inhibited the 
aggregation of rabbit platelets induced by arachidonic acid, collagen, and 
platelet activating factor (Tsai et al； 1996). On the other hand, Wang et al. 
demonstrated that bakuchiol and corylin exerted exhibited osteoblastic 
proliferation stimulating activity in UMR106 cells (Wang et al., 2001). Corylin 
also increased ALP activity in these cells in other study and it was suggested 
that corylin might stimulate bone formation (Xiong et al., 2003). Psoralen and 
isopsoralen have anticancer activity (Guo et al., 2003). They were also 
demonstrated to exhibit in vitro inhibitory actions on monoamine oxidase 
activities in rat brain mitochondria, and they may have potential applications 
to treat affective disorders (Kong et al., 2001). 4'-methoxy flavone shows 
antidermatophytic effect (Rajendra Prasad et al., 2004). Psoralidin, 
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bakuchicin, psoralin and angelidn show antibacterial activities (Khatune et al” 
2004). 
' . . . . 
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4.7 Limitations of the present studies 
In the animal study, only the effects of the aqueous and ethanol extracts 
of ELP and two of its ingredients, Epimedium and Ligustrum on the 
ovariectomized rats were studied. The remaining ingredient of ELP, Psoralea, 
was excluded from the present study owing to inadequate manpower. 
Because of it, the reasons for distinct effect between the ethanol extracts of 
ELP, and Epimedium/Ligustrum on the gene expression of renal 1a-0Hase 
cannot be ruled out. It may be caused by the synergetic interaction between 
the three ingredients in ELP or just only the effect of Psoralea. 
For assessing the effects of the extracts of ELP, Epimedium and 
Ligustrum on calcium homeostasis in the animal study, the mRNA 
expressions of calcium absorption and reabsorption related genes were 
measured. However, gene expression analysis is only an indirect parameter 
to assess calcium homeostasis. In addition, there are numerous genes 
involved in calcium absorption and reabsorption, and only the expressions of 
those, which are well studied and play major roles in calcium homestasis, 
were examined in the present study. Moreover, the selected herbal extracts 
may also influence expressions of the selected gene post-transcriptionally, 
which could not be monitored in the gene expression study. In view of these, 
a direct calcium balance measurement by calculating calcium intake and 
measuring calcium content in faeces and urine could be more definitive. 
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in the cell culture study, the human breast cell line MCF-7 expresses 
both ERa and ERp. In the competitive estrogen receptor binding assay, the 
aqueous extract of Epimedium showed estrogen receptor binding activity. 
However, whether it binds ERa or ERp or both remains obscured. It is known 
that ERa and ERp have distinctly different localizations and concentrations 
within our body, as well as structural differences, which allow distinct 
biological roles between them (Gustafsson, 1999). Previous studies have 
demonstrated that at least one mechanical strain-related cascade 
responsible for adaptive control of bone architecture is mediated through 
ERa, and possibly modified by ERp (Lanyon et al., 2004). This showed that 
both ERa and ERP involved in bone physiology. Specific binding assay to 
distinguish whether the aqueous extract of Epimedium binds ERa or ERp 
could give an insight into the underlying mechanisms of its actions. 
it is a pity that only the aqueous extracts of Epimedium and Ligustrum 
on bone formation were assessed, due to time limitation. Besides, based on 
the results that the aqueous and ethanol extracts of ELP, Epimedium and 
Ligustrum reduced spinal BMD loss in the animal study, it is speculated that 
modulation in bone resorption may play a major role in preservation of spinal 
BMD. As a matter of fact, almost all therapeutic agents used in the 
prevention and treatment of osteoporosis exert their actions through reducing 
bone turnover or suppressing bone resorption (Delmas, 2002). Thus, the 
direct effects of the selected herbal extracts on bone resorption are worth 
studying, but there is not enough time to examine them in osteoclastic cell 
line model in the present studies. 
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4.8 Conclusion and future prospect 
The aqueous and ethanol extracts of the Kidney-tonifying herbal formula, 
ELP, and its major ingredients, Epimedium and Ligustrum are, in general, 
safe to administrate and exhibit favorable effects on BMD. To further the 
study, the actions of the extracts of Epimedium, Ligustrum and ELP at the 
cellular and molecular levels were investigated. 
The aqueous and ethanol extracts of Kidney-tonifying herbs and herbal 
formula modulated the expression of the calcium absorption and 
reabsorption-related genes of ovariectomized adult rats in the present studies. 
The ethanol extract of the Kidney-tonifying herbal formula, ELP, induced the 
gene expression of renal 1a-0Hase, which could increase the synthesis of 
1 ,25(0H)2D3. The ethanol extract of Ligustrum increased the mRNA level of 
duodenal VDR, which is the mediator of 1’25(OH)2D3-induced calcium 
absorption. The aqueous extract of Epimedium and ELP upregulated the 
gene expression of renal VDR and CaBP-D28K respectively, which are 
involved in calcium reabsorption. Apart from having significant effects on the 
expressions of genes related to calcium absorption and reabsorption, the 
aqueous extract of Ligustrum also mildly modulated the bone matrix 
mineralization and the aqueous extract of Epimedium showed estrogen 
receptor binding activity. These observations suggest that the selected 
Kidney-tonifying herbs and herbal formula positively modulate calcium 
homeostasis and, probably, bone matrix mineralization, which could favor 
bone protection, and it is speculated that estrogen receptor may be one of 
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the mediators of these actions. This suggests the potential clinical use of the 
aqueous and ethanol extracts of the Kidney-tonifying herbal formula, ELP, 
and its major ingredients, Epimedium and Ligustrum on the treatment of 
postmenopausal osteoporosis. 
Future studies are necessary to investigate the direct effects of the 
aqueous extract of ELP, and the ethanol extracts of Epimedium, Ligustrum 
and ELP on osteoblastic cells and their estrogen receptor binding activities in 
the in vitro system, which have not been examined in the present studies. 
For the study on bone metabolism, we have not yet investigated the 
effects of the Kidney-tonifying herbs and herbal formula on 
osteoclastogenesis and bone resorption, which can be stimulated by 
estrogen deficiency and aggravate postmenopausal osteoporosis. In the 
animal study, the levels of bone resorption marker urinary total 
deoxypyridinoline (Dpd) reduced significantly by 34% to 46% in the herbal 
extract-feeding groups (Data not shown, performed by Mr. Sun Ye, personal 
communication). Thus, it is worthy to examine whether the reduction in bone 
resorption is associated with the direct effects of the herbal extracts on the 
survival and functions of osteoclasts and bone resorption using in vitro model. 
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